

**UNITED STATES AIR FORCE
ARMSTRONG LABORATORY**

**PHYSIOLOGICALLY BASED
PHARMACODYNAMIC MODELING
OF CHEMICALLY INDUCED
OXIDATIVE STRESS**

**J.Z. Byczkowski
C.D. Flemming**

MANTECHGEO-CENTERS JOINT VENTURE
P.O. BOX 31009
DAYTON, OH 45437

**M.A. Curran
C.R. Miller
W.J. Schmidt
A.P. Moghaddam
S.R. Channel**

TOXICOLOGY DIVISION
OCCUPATIONAL & ENVIRONMENTAL HEALTH DIRECTORATE
2856 G STREET, BLDG 79
WRIGHT-PATTERSON AFB, OH 45433-7400

September 1997

DTIC QUALITY INSPECTED 2

Occupational and Environmental Health
Directorate
Toxicology Division
2856 G Street
Wright-Patterson AFB OH 45433-7400

Approved for public release; distribution is unlimited.

19990427 013

NOTICES

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Air Force Research Laboratory. Additional copies may be purchased from:

National Technical Information Service
5285 Port Royal Road
Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Service
8725 John J. Kingman Rd., Ste 0944
Ft. Belvoir, Virginia 22060-6218

DISCLAIMER

This Technical Report is published as received and has not been edited by the Technical Editing Staff of the Air Force Armstrong Laboratory.

TECHNICAL REVIEW AND APPROVAL

AL/OE-TR-1997-0145

The animal use described in this study was conducted in accordance with the principles stated in the "Guide for the Care and Use of Laboratory Animals", National Research Council, 1996, and the Animal Welfare Act of 1966, as amended.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE DIRECTOR



STEPHEN R. CHANNEL, Maj, USAF, BSC
Branch Chief, Operational Toxicology Branch
Air Force Research Laboratory

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1997		3. REPORT TYPE AND DATES COVERED Interim Report - December 1994-May 1997
4. TITLE AND SUBTITLE Physiologically Based Pharmacodynamic Modeling of Chemically Induced Oxidative Stress			5. FUNDING NUMBERS Contract F41624-96-C-9010 PE 61102F PR 2312 TA 2312A2 WU 2312A202	
6. AUTHOR(S) J.Z. Byczkowski, C.D. Flemming, M.A. Curran, C.R. Miller, W. J. Schmidt, A.P. Moghaddam, and S.R. Channel				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ManTech Geo-Centers Joint Venture P.O. Box 31009 Dayton, OH 45437-0009			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Armstrong Laboratory, Occupational and Environmental Health Directorate Toxicology Division, Human Systems Center Air Force Materiel Command Wright-Patterson AFB, OH 45433-7400			10. SPONSORING/MONITORING AGENCY REPORT NUMBER AL/OE-TR-1997-0130	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Health risk from chemicals depends on both the extent of exposure and a dose-response relationship, which is reflecting, in turn, the mode of action of chemicals. For quantitative modeling of the mode of action it is necessary to determine the exact chain of events of the chemical interaction with the biological system. To provide a tool potentially useful for risk characterization of pro-oxidant chemicals, a quantitative mathematical model (physiologically based pharmacodynamic or PBPD model) describing biological effects within the target organ was constructed in a way compatible with traditional pharmacokinetic (PBPK) models which describe the internal, local dose of a chemical. Based on the available literature and our own experimental data, the three basic modes of action of pro-oxidant chemicals were modeled and simulated <i>in silico</i> : i. lipid peroxidation (expressed by the formation of thiobarbituric acid reactive substance (TBARS) and the exhalation of ethane); ii. specific interaction of free radicals with homogenous cellular targets; and iii. random interaction of free radicals with multiple cellular targets. Based on the dose-response characteristic verified <i>in vitro</i> , a PBPD model of chemically initiated oxidative stress was developed and calibrated in B6C3F1 mice. The model consisted of three major modules. At first, a biologically based module for chemically induced lipid peroxidation was developed and calibrated <i>in vitro</i> using precision cut mouse liver slices. Next, the parameters describing the mechanism of action of pro-oxidant chemicals were applied to the physiologically based pharmacodynamic module describing chemically induced lipid peroxidation in mice <i>in vivo</i> .				
14. SUBJECT TERMS			15. NUMBER OF PAGES 110	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED		18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED		19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED
				20. LIMITATION OF ABSTRACT UL

THIS PAGE INTENTIONALLY LEFT BLANK.

PREFACE

This report describes the results of the development, experimental calibration and predictions of a physiologically based pharmacodynamic model simulating biological effects of oxidative stress induced by chemicals *in vitro* and *in vivo*. This is one of a series of technical reports and publications describing results of a collaborative effort conducted by ManTech Environmental Technology, Inc., Toxic Hazards Research Unit, located at Wright-Patterson Air Force Base, and by Occupational and Environmental Health Directorate, Toxicology Division, and aimed at pharmacodynamic description of biological effects.

The animals used in this study were handled in accordance with the principles stated in the *Guide for the Care and Use of Laboratory Animals* prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, National Academy Press 1996, and the Animal Welfare Act of 1966, as amended.

Research performed by ManTech Environmental Technology was conducted under Department of the Air Force Contract No. F41624-96-C-9010. Lt Col Terry A. Childress, Director of the Toxicology Division, served as Contract Technical Monitor.

TABLE OF CONTENTS

SECTION	PAGE
PREFACE.....	iii
TABLE OF CONTENTS.....	iv
LIST OF TABLES AND FIGURES.....	vii
ABBREVIATIONS	ix
INTRODUCTION	1
Chemically Induced Oxidative Stress.....	1
Lipid Peroxidation	2
Biomarkers Of Lipid Peroxidation.....	3
Risk Characterization Of Pro-Oxidant Chemicals Based On Their Mode Of Action.....	5
MATERIALS AND METHODS.....	8
Chemicals.....	8
Dosage.....	8
Animals	8
Measurement of Lipid Peroxidation <i>In Vitro</i>	8
Free Radical Measurement	10
Animal Treatment and Measurement of Lipid Peroxidation <i>In Vivo</i>	10
Animal Treatment	10
Air Sample Analysis	11
Partition Coefficients	11
Mathematical Modeling and Computer-Assisted Simulations	12

RESULTS	13
Model Structure	13
Modules.....	13
PBPK Sub-Model for Internal Dose of Pro-Oxidant Chemical.....	14
Classic PK Module for Intraperitoneal Dosing of Pro-Oxidant Chemicals.....	14
BBPD Module for Activation of Pro-Oxidant Chemicals and Free Radical Concentration.....	15
BBPD Sub-Model for Lipid Peroxidation	16
BBDR Sub-Model for Cellular Target Inhibition.....	16
Deterministic Module	18
Stochastic Module.....	18
Parametrization and Calibration of Sub-Models with Data.....	19
PBPK Sub-Model for Internal Dose of Pro-Oxidant Chemical.....	19
Classic PK Module for Intraperitoneal Dosing of Pro-Oxidant Chemicals.....	20
BBPD Module for Activation of Pro-Oxidant Chemical and Free Radical Concentration.....	20
BBPD Sub-Model for Lipid Peroxidation	20
Verification of BBPD Sub-Model for Lipid Peroxidation <i>in vitro</i>	25
Verification of BBPD Sub-Model for Lipid Peroxidation <i>in vivo</i>	25
BBDR Sub-Model for Cellular Target Inhibition.....	29
Deterministic Module	29
Stochastic Module.....	31
DISCUSSION.....	36
PBPD Model	36

Oxidative Stress and Lipid Peroxidation	39
Comparison of Pro-Oxidant Chemical Concentrations <i>in vitro</i> vs <i>in vivo</i>	40
Effects of Pro-Oxidant Chemicals on Lipid Peroxidation	41
Effects of Free Radicals on Cellular Targets	42
Setting a Hypothesis with the PBPD Model	43
CONCLUSION	45
ACKNOWLEDGMENTS	45
REFERENCES	46
APPENDIX: Source Codes of PBPD Model Written in ACSL	53

LIST OF TABLES AND FIGURES

TABLE	PAGE
1 Chemical-dependent pharmacokinetic parameters for TCE and CCl ₄	19
2 Pharmacodynamic parameters for TCE and CCl ₄ in B6C3F1 mice.....	22
3 Pharmacokinetic parameters for ethane exhalation in B6C3F1 mice.....	27
4 Parameter for the biologically based pharmacodynamic model.....	33

LIST OF FIGURES

FIGURE	PAGE
1 Antioxidant defense system	2
2 Pro-oxidant chemicals and free radicals involved in oxidative stress	3
3 A scheme of lipid peroxidation process.....	4
4 Risk characterization combines dose-response with exposure	5
5 Conceptual framework of oxidative stress modeling.....	6
6 Modular structure of PBPD sub-model for chemically induced lipid peroxidation	13
7 PBPD sub-model for lipid peroxidation	17
8 BBPD module: effect of TCE on generation of free radicals	21
9 BBPD module: effects of TCE on lipid peroxidation.....	22
10 BBPD module: effects of TCE on lipid peroxidation.....	23
11 Effects of BrCCl ₃ on TBARS production.....	24
12 Effects of BrCCl ₃ on thane exhalation.....	25
13 Time-dependent effects of BrCCl ₃ on thane exhalation	26
14 BBPD module: effects of CCl ₄ on lipid peroxidation	27

15	PBPD: closed chamber ethane gas uptake	28
16	PBPD: effects of TCE on ethane exhalation in mice	29
17	PBPD: effects of CCl ₄ on ethane exhalation by mice <i>in vivo</i>	30
18	BBPD model: dose-dependent effects of CCl ₄ on ethane exhalation <i>in vivo</i>	31
19	BBPD deterministic module calibration with <i>in vitro</i> data.....	32
20	BBDR stochastic module calibration with <i>in vitro</i> data	34
21	BBDR calibration of sub-model with <i>in vitro</i> data.....	35
22	BBDR: effect of Cum.OOH on glucose transporter	35
23	PBPD model: interlinked BBPD/PBPK description of oxidative stress.....	36
24	Representations of free radical steady state concentrations.....	38
25	Representations of free radical interactions with cellular targets	39
26	BBDR: simulated effects of TCE on P _{tyr} Pase activity	44

ABBREVIATIONS

ACSL	Advanced continuous simulation language
AUC	Area under the concentration curve
BBDR	Biologically based dose response
BHT	Butylated hydroxytoluene
BrCCl ₃	Bromotrichloromethane
CCl ₄	Carbon tetrachloride
CYP	Cytochrome P450
DMNQ	2,3-dimethoxy-1,4-naphtoquinone
EPR	Electron paramagnetic resonance
GC	Gas chromatography
GSH	Glutathione
h	Hour
i.p.	Intraperitoneal
L	Liter
MAPK	Mitogen activated protein kinase
min	Minute
MTT	3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
O ₂ ^{•-}	Superoxide anion radical
PBN	N-tert-butyl- α -nitron
PBPD	Physiologically based pharmacodynamics
PBPK	Physiologically based pharmacokinetics
PD	Pharmacodynamic
PK	Pharmacokinetic
ppm	Parts <i>per</i> million
SD	Standard deviation
SOD	Superoxide dismutase
TBARS	Thiobarbituric reactive substance
TBOOH	tert-Butyl hydroperoxide
TCE	Trichloroethylene

INTRODUCTION

CHEMICALLY INDUCED OXIDATIVE STRESS

Pro-oxidant chemicals are those compounds that may bring about a state of excess one-electron oxidations, either directly or indirectly *via* metabolic breakdown. Oxidative stress is a pathophysiological process in which the balance between pro-oxidants and antioxidants in tissue is shifted towards pro-oxidants (Figure 1; Byczkowski and Channel, 1996). Pro-oxidant chemicals may be provided by environmental, occupational, or therapeutic exposure to xenobiotics (Kehrer, 1993), may arise from dietary polyunsaturated fat (Gower, 1988; Finley and Otterburn, 1993; Haeghele et al., 1994), or may be produced endogenously during physiological function of aerobic cells (Byczkowski and Gessner, 1988). From the primary pro-oxidant chemical, further metabolic reactions generate free radicals (defined as molecules or groups of atoms with one unpaired electron), and then, an avalanche-type process (e.g., lipid peroxidation) may release secondary and tertiary free radicals (Figure 2; for review see Roberfroid and Calderon, 1994). Additional factors, such as aging (Stadtman et al., 1993) or dietary deficiencies, may augment the oxidative stress status. Depletion of cellular antioxidants, as well as defective enzymatic scavenging systems, further increase oxidative stress and may enhance damage to cellular components. Oxidative stress can be reversed by natural and synthetic antioxidants (Williams, 1993; Papas, 1993; Pratt, 1993). Possible definitions and implications of oxidative stress and the basic literature on its measurement were reviewed in a recent publication by Byczkowski and Channel (1996).

Several chemicals can cause an oxidative stress directly (e.g., by generating free radicals during metabolism by cytochrome P450 (CYP) or during redox cycling; Kappus, 1986) or indirectly (e.g., by stimulating a respiratory burst in inflammatory cells; Kulkarni and Byczkowski, 1994a). In addition, several natural and synthetic peroxides (e.g., tumor-promoting organic hydroperoxides; Taffe et al., 1987; Timmins and Davies, 1993) can be cleaved by trace amounts of the transition metals, directly producing highly reactive free radicals without involvement of enzymatic metabolic pathways (Kulkarni and Byczkowski, 1994b). Chemically induced oxidative stress causes derangement of antioxidant mechanisms in tissues (Videla et al., 1990), may lead to lipid peroxidation (Comporti, 1985), inhibition of cellular enzymatic activities (e.g., CYP activity; Willis, 1980) and may result in cell injury (de Groot and Littauer, 1989). It has been demonstrated that lipid peroxidation may cause necrotic tissue damage rather than be an effect of necrosis (Biasi et al., 1995).

Antioxidant Defense System




Figure 1. Cellular balance between pro-oxidants capable of inducing oxidative stress (ΔgO_2 - singlet oxygen; $OH^\bullet$ - hydroxyl radical; $R^\bullet$ - carbon-, nitrogen- or oxygen-centered free radical; $O_2^{\bullet -}$ - superoxide anion radical; $-O-O^\bullet$ - peroxy radical; H_2O_2 - hydrogen peroxide), and intracellular antioxidants (SOD - superoxide dismutase; Catalase; GSH-Px - glutathione peroxidase; GSH - glutathione; Tocopherol - vitamin E; Ascorbate - vitamin C; β -Carotene; modified from Byczkowski and Channel, 1996; according to Bray and Betteger, 1990).

LIPID PEROXIDATION

Lipid peroxidation is a pathological process leading to a unique form of hepatocellular injury implicated in the genesis of liver necrosis evoked by several pro-oxidant chemical hepatotoxicants (e.g., carbon tetrachloride - CCl_4 , yellow phosphorous, ethanol, etc.; Kulkarni and Byczkowski, 1994a), and it may be linked with carcinogenicity (Byczkowski and Channel, 1996). Lipid peroxidation is characterized by the formation of conjugated dienes, formation of thiobarbituric acid reactive substance (TBARS; mainly malondialdehyde), and the exhalation of alkanes (e.g., ethane). TBARS and ethane are generated, among other stable products, during the propagation and termination of lipid peroxidation process (Figure 3). The alkanes are formed in biological systems through peroxidation of the omega-3 (ethane) or omega-6 (pentane) fatty acids and the subsequent beta-scission decomposition of the intermediate hydroperoxides (Gardner, 1989).

Pro-Oxidant Chemicals and Free Radicals Involved in Oxidative Stress




Figure 2. Free radicals and reactive oxygen species involved in the chemically induced oxidative stress (modified from Byczkowski and Channel, 1996, according to Trush and Kensler, 1991).

BIOMARKERS OF LIPID PEROXIDATION

Based on the findings of Riely et al. (1974) that mice treated with carbon tetrachloride have an increased amount of the exhaled ethane *in vivo*, numerous studies have been conducted in which ethane and/or pentane were measured as indices of lipid peroxidation or surrogate biomarkers of tissue damage by oxidative stress. Increased ethane exhalation was also found by Cojocel et al. (1989) as a consequence of lipid peroxidation in mice treated with trichloroethylene (TCE). Consequently, volatile alkane (ethane and/or pentane) detection in expired air has been used for some time as a non-invasive technique to measure lipid peroxidation in whole animals or human subjects (Refat et al., 1991; Kazui et al., 1992; Arterbery et al., 1994; Guilbaud et al., 1994). Ethane exhalation is more reliable as an index of lipid peroxidation than pentane, because CYP-mediated metabolism of ethane is substantially slower than that of pentane (Smith, 1991).

A Scheme of Lipid Peroxidation Process




Figure 3. A simplified scheme of lipid peroxidation reactions which lead to production of thio-barbituric acid reactive substances (TBARS) and to generation of ethane (according to Sagai and Ichinose, 1980). Me^{2+} - transition metal cation.

Typically, in the assay, exhaled air is probed for ethane by gas chromatography using flame ionization, photoionization, or ion trap detectors (Kneepkens et al., 1994). Because of its direct

relation to lipid peroxidation (Jeejeebhoy, 1991; Figure 3), we chose ethane exhalation assay as an end point for development of the computer-aided PBPD model for simulation of the biological effects caused by CCl_4 , TCE, and other pro-oxidant chemicals (tert-butyl hydroperoxide and bromotrichloromethane, BrCCl_3).

The measurement of rates of TBARS generation *in vitro* was used previously for calibration of the biologically based pharmacodynamic model (BBPD) of lipid peroxidation induced by tert-butyl hydroperoxide and BrCCl_3 in mouse liver slices, described elsewhere by Byczkowski et al. (1995; 1996). In the present report, a physiologically based pharmacodynamic (PBPD) model of lipid peroxidation is described which employs ethane exhalation as a measurable end point *in vivo* and incorporates the previously developed *in vitro* model as a mechanistic module. The developed PBPD model has been linked with a PBPK sub-model that describes the local concentrations of CCl_4 and TCE in the liver. The resultant hybrid PBPD model may be used for a pharmacodynamic description of oxidative stress, dose-response characterization, and risk characterization of pro-oxidant chemicals.

RISK CHARACTERIZATION OF PRO-OXIDANT CHEMICALS BASED ON THEIR MODE OF ACTION

Health risk from chemicals depends on both the extent of exposure and a dose-response relationship, which reflects, in turn, the mode of action of chemicals (Figure 4).

Risk Characterization Combines Dose-Response with Exposure




Figure 4. A paradigm for risk characterization.

Because biological responses of tissues and organs are mechanistically linked to local concentration of the active form of xenobiotic, the internal dose of chemical that reaches a particular physiological compartment must be used for any meaningful risk characterization.

Without understanding "what the particular dose of a chemical can do to the organism" the whole process of risk characterization is useless to a risk manager (Figure 4).

In addition to the question about the direct biological effect of the delivered concentration of an activated (free radical) form of the pro-oxidant chemical, other important questions are: i. "How is the target organ protected against free radical insult?"; ii. "How fast are normal (physiological) processes of autooxidation?"; and iii. "How fast do the activating enzymes (CYP) degrade?"

For quantitative characterization and modeling of the dose-response for pro-oxidant chemicals (e.g., CCl_4 , BrCCl_3 , or TCE) it was necessary not only to answer these questions, but also to include the mode of action and to determine the exact chain of events in the chemical interaction with the biological system (Figure 5).




Figure 5. A conceptual framework for quantitative modeling and dose-response characterization of the chemically induced oxidative stress.

At first, the internal delivered dose of pro-oxidant chemical has been described as a function of exposure with an appropriate pharmacokinetic (PK and/or PBPK) model. Then, the local concentration of free radicals, generated by the pro-oxidant chemical, has been described as a function of the local dose of the chemical with an appropriate BBPD model. Next, using

mechanistic information, oxidative stress and lipid peroxidation have been described as functions of free radical concentration. Finally, the health effects may be quantitatively described by biologically based dose-response (BBDR) sub-model as continuous or discrete phenomena, depending on the magnitude of oxidative stress. The dependence may be either deterministic or stochastic in nature. These considerations, based on the available literature and experiments conducted in our laboratory, led to the development, calibration, and partial verification of the hybrid PBPD model for chemically induced oxidative stress. The resultant computer-assisted simulation model described in this report may be useful for risk characterization of pro-oxidant chemicals.

MATERIALS AND METHODS

CHEMICALS

All chemicals used in this study were of analytical grade. N-tert-butyl- α -nitron (PBN) and 2,2,5,5,-tetramethyl-1-pyrrolidinyloxy-3-carboxamide (3-CAR) were purchased from Aldrich Chemical Co., Inc., Milwaukee, WI. Dimethyl sulfoxide (DMSO), BHT, CCl_4 , BrCCl_3 , TCE, and TBOOH were from Sigma Chemical Co., St. Louis, MO.

Dosage

The pro-oxidant chemicals tested: carbon tetrachloride (CCl_4), bromotrichloromethane (BrCCl_3), trichloroethylene (TCE), and tert-butyl hydroperoxide (TBOOH) were used *in vitro* or *in vivo* in the following concentrations or doses:

Liver slices *in vitro* (recalculated as final concentrations in the medium):

CCl_4 - 0.1, 0.5, 1.0, and 1.5 mM

BrCCl_3 - 0.1, 0.5, 1.0, and 1.5 mM

TCE - 0.1, 0.5, 1.0, and 1.5 mM

TBOOH - 0.1, 0.5, 1.0, 1.5 mM

Mice *in vivo* (single i.p. doses expressed per body weight):

CCl_4 - 0.075, 0.15, 0.3, and 1.5 g/kg

BrCCl_3 - 0.025, 0.05, 0.1, and 1.0 g/kg

TCE - 0.26, 1.0, and 2.6 g/kg

TBOOH - 0.025, 0.05, 0.1, and 0.225 g/kg

ANIMALS

The B6C3F1 male mice (Charles River Breeding Laboratories, Kingston, NY), 25 - 38 g body weight were used throughout the study. Routinely, the mice were provided with Purina Formulab 5008 standard diet and *Pseudomonas*-free softened water *ad libitum*. One week before experiment, the diet was switched to the vitamin A- and E- deficient, purified diet Purina 5827C-1.

MEASUREMENT OF LIPID PEROXIDATION *IN VITRO*

Precision-cut slices were prepared from livers of B6C3F1 male mice and maintained using the dynamic roller culture method (Sipes, et al., 1987; Brendel et al., 1993). The mice were euthanized with CO_2 , their livers were removed and placed in ice-cold Sacks buffer (containing: KH_2PO_4 0.75 g/L, K_2HPO_4 9.5 g/L, NaHCO_3 1.2 g/L, KHCO_3 0.6 g/L, mannitol 37.5 g/L, and MgCl_2 ; pH 7.4).

Liver cores, 8 mm diameter, were prepared and sliced in ice-cold Sacks buffer using a Krumdieck tissue slicer (Alabama Research and Development, Munford, AL; Brendel et al., 1987; Krumdieck et al., 1980). The slices were loaded on rollers (two slices per roller) in ice-cold Sacks buffer. The rollers were then placed in scintillation vials containing 1.7 mL of Waymouths MB 752/1 media at 37 °C (Formula 78-5107EC, without phenol red, pH 7.4, Gibco BRL, Grand Island, NY), supplemented with NaHCO₃ 1.3 g/L, HEPES 2.38 g/L, NaCl 0.292 g/L, l-glutamine 0.35 g/L, gentamycin sulfate 50 mg/L, and 10% fetal bovine serum (Hyclone, Logan, UT), and capped with a scintillation vial cap with 1/4" hole for gas exchange. The vials were placed in a Dynamic Roller Culture Incubator (Vitron, Tucson, AZ) and gassed with 95% O₂/5% CO₂ for a 2-h preincubation period.

After a 2-h preincubation period, the rollers were removed from the vials, placed into prewarmed, sealed vials containing fresh media (pH 7.4), and dosed through the septa with either vapors (for volatile chlorinated hydrocarbons: CCl₄, BrCCl₃, TCE) or an appropriate dilution (for water-soluble compound, TBOOH) of pro-oxidant chemical at the desired final concentration. The dosed vials containing rollers were then returned to the roller culture incubator. Final concentrations of volatile pro-oxidant chemicals in the media were calculated using partition coefficients, determined for the equilibrated medium/air system at 37 °C (for CCl₄ 0.666 [$\pm$ 0.05 S.D., n=15], for BrCCl₃ 1.97 [$\pm$ 0.23 S.D., n=18], for TCE 1.94 [$\pm$ 0.17 S.D., n=18]). Zero time controls were processed immediately. Then, the vials were removed at intervals over a 2-h incubation and slices were weighed and sonicated in their own media. Finally, aliquots of each sonicated sample were removed for TBARS assay and protein content measurements. Samples for TBARS assay were added to ice-cold D-PBS/GSH/EDTA buffer (pH 7.4) containing 20 mg reduced GSH and 48 mg EDTA in 100 mL D-PBS (Dulbecco's buffer; Gibco BRL, Grand Island, NY). Incubations were repeated several times with different liver preparation (typically, n=4).

Lipid peroxidation was measured by the formation of TBARS, employing the fluorescence spectrophotometry of solvent tissue extracts (Janero, 1990). Essentially, in this assay, the aldehyde products generated by splitting the endoperoxide alkoxyl radicals (formed during the peroxidation of unsaturated fatty acids; mostly malondialdehyde, MDA) reacted with thiobarbituric acid (TBA) to yield a 1:2 MDA:TBA red, fluorescent, complex (Janero, 1990). Incubation of liver slices without chemical inducer did not significantly increase the fluorescence for up to 2 hours. Since the control values for liver slices at time zero were subtracted from the results, under conditions of the assay, the determined amount of MDA:TBA complex reflected the extra amount of lipid hydroperoxides produced in addition to the normal physiological background.

At 1 hour and 2 hours of incubation, the samples of liver slices (control and treated) were removed for viability analysis. The viability was assessed from lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) leakage, and intracellular potassium content. The enzyme leakage was determined using a Kodak Ektachem Analyzer (model 700XR) for aminotransferase activities and DuPont acaV for dehydrogenase activity. An acceptable enzyme leakage level for precision-cut liver slices was assumed to be less than 20% of the total content of enzymatic activity. Potassium content in sonicated tissue samples was determined using an AVL 982-S Electrolyte Analyzer (Roswell, GA). The acceptable level of intracellular potassium content in precision-cut liver slices was assumed to be greater than 35 mM K⁺/g wet weight. If the average viability tests of either control or treated liver samples did not meet the above acceptable levels, the experimental results were discarded.

Free Radical Measurement

Known amounts of a spin label (N-tert-butyl- α -nitron, PBN) were added to liver slices in Waymouth's media and incubated with or without addition of appropriate pro-oxidant chemical (1 mM CCl₄, BrCCl₃, TCE, TBOOH, for 60 min.). The radicals generated by these chemicals formed adducts with PBN which were detected by the electron paramagnetic resonance (EPR) spectroscopy (Buettner, 1987). The total radicals in the lyophilized samples of liver slices were measured using a Bruker EMS 104 EPR analyzer. The machine parameters for the EPR analyzer were: microwave power, 25 mW; sweep width, 100 G; modulation amplitude, 4.02 G; sweep time, 10.49 s; filter time constant, 20.48 ms; receiver gain, 60. The spectra were measured by peak height directly from the EMS 104 EPR analyzer and by double integration with normalization for receiver gain using the EPR program (Bruker, Billerica, MS).

All results were recalculated per liver dry weight and analyzed by one-way and two-factorial analysis of variance using the statistics package Design Ease®. The factors were concentration and time. Standard deviations and regression correlation were performed using Sigma Plot®.

ANIMAL TREATMENT AND MEASUREMENT OF LIPID PEROXIDATION *IN VIVO*

Animal Treatment

Male B6C3F1 mice (body weight 29 - 32 g), fed for one week the vitamin A- and E- deficient diet, were used to conduct the exhalation experiments and partition coefficient determinations. Animals were treated intraperitoneally (i.p.) with pro-oxidant chemicals at appropriate doses (calculated in g/kg body weight), dissolved in 0.2 mL of mineral oil. Immediately after treatment,

ethane production was monitored using a closed gas uptake system (Gargas et al., 1986). Four or five mice were placed simultaneously in a 0.75 L chamber containing 50 grams of soda lime that absorbs CO₂ and H₂O. Chamber oxygen concentration was monitored (MDA oxygen analyzer, MDA Scientific, Lincolnshire, IL) and kept at a range of 20-21.5% throughout the exposure. Ethane exhalation measurements were repeated several times with different groups of mice before and after the treatment (typically, n=4).

Air Sample Analysis

Samples were collected using an automatic sampling valve (1 mL sample loop) connected to a Hewlett Packard 5890 GC. Ethane was separated from other respiratory gases by a 6' x 1/8" stainless steel column packed with Chromosorb 102, 80-100 mesh (Alltech, Deerfield, IL). The column temperature was 50 °C, and the injector and flame ionization detector temperatures were 125 °C and 200 °C, respectively. A carrier gas (nitrogen) flow rate was set at 20 mL/min and the air *plus* hydrogen flow rate was 405 mL/min. The retention time was 2.1 min after the valve opened. A Hewlett-Packard 3396 Integrator was used to measure peak heights; and ethane concentrations were calculated using a calibration curve prepared with ethane standards.

A background noise at low levels of ethane as well as the ethane detection threshold and peak integration by GC and data-processing software were responsible for a quantification threshold, below which any measurement of ethane concentration was uncertain. Due to this uncertainty, a reliable ethane quantification level by the method used was above approximately 0.025 ppm. (minimum ethane concentration integrated as a peak by GC + 2 SD).

Partition Coefficients

Partition coefficients for ethane were determined in our laboratory (Seckel and Byczkowski, 1996) using a modified vial-equilibration method *in vitro*, described by Gargas et al. (1989). Tissues from five B6C3F1 mice were pooled, homogenized, and aliquoted into 12.4 mL headspace analyzer vials. Tissues analyzed included: blood, liver, fat, kidney, and muscle. Each tissue sample weighed 1 gram. To inhibit spontaneous lipid peroxidation, butylated hydroxytoluene (BHT; Sigma Chemical, St. Louis, MO) was added in the amount of 5 mg/g tissue. A 15 ppm concentration of ethane gas was added to the headspace of each vial. The vials with constituents were vortexed for 3 h at 37 °C. A sample was removed from the headspace of each vial *via* a Hewlett Packard 19395A autosampler. A Hewlett Packard 5890 GC was used to analyze samples with data handled by a P. E. Nelson Data Acquisition System equipped with Turbochrom (version 4.0) software. A Poraplot Q, 25 m x 0.53 mm (Chrompak, The Netherlands), was used for chemical separation along with the following GC conditions: oven temperature 100 °C, injector temperature 100 °C, flame ionization

detector 250 °C, and N₂ carrier flow through column and headspace sampler 5.3 cc/min. Ethane retention time was determined at 1.58 min.

MATHEMATICAL MODELING AND COMPUTER-ASSISTED SIMULATIONS

Ethane metabolism parameters ($V_{\max}$ and K_m) were estimated, fitted, and optimized with the PBPD model which was based on our *in vivo* experimental measurements of ethane uptake in a closed chamber, using the method for volatile chemicals essentially as described by Gargas et al. (1986). Partition coefficients were determined using the method of Gargas et al. (1989), as described above. The PBPD model was written in Advanced Continuous Simulation Language (ACSL; Mitchell and Gauthier Associates, Inc. 1993) with a sub-routine written in FORTRAN. The simulations were performed using SIMUSOLV® software with optimization capabilities (Steiner et al., 1990) on a VAX/VMS minicomputer. Parameters were optimized by SIMUSOLV®, which uses the log likelihood function as the criterion. Either the generalized reduced gradient method for single parameter optimization or the Nelder-Mead search method for multiple parameters optimization was used to adjust the values (Steiner et al., 1990).

RESULTS

MODEL STRUCTURE

Modules

The PBPD model for chemically induced oxidative stress was composed of several modules, interlinked to form integral sub-models (Figure 6). Each sub-model was calibrated and verified individually with experimental data from our laboratory and/or from the available literature.

Modular Structure of PBPD Sub-Model for Chemically Induced Lipid Peroxidation




Figure 6. A simplified scheme of physiologically based pharmacodynamic (PBPD) sub-model for chemically induced lipid peroxidation.

The model, describing biological effects within the target organ, was constructed in a way compatible with physiologically based pharmacokinetic (PBPK) module and/or classic compartmental pharmacokinetic (PK) module which estimated the internal dose of a chemical. The biologically based pharmacodynamic (BBPD) module described bioactivation of a chemical (decreased by cytochrome P450 (CYP) degradation and suicidal inhibition), production of free radicals (quenched by antioxidants), and lipid peroxidation (enhanced by autooxidation) accompanied by TBARS and ethane generation. The PBPD module described distribution and exhalation of ethane.

PBPK Sub-Model for Internal Dose of Pro-Oxidant Chemical

The PBPK sub-model for internal dose of pro-oxidant chemicals was constructed as a traditional, flow-limited PBPK mathematical description of volatile compounds (Gargas et al., 1986; Yang and Andersen, 1994). A separate input compartment, parallel to the gastrointestinal tract, was added to this sub-model to estimate intraperitoneal exposure. The rate of change in the amount of chemical absorbed from the peritoneal cavity (RA_{ip} [mg/h]) was described as a product of the rate constant of absorption (KA_{ip} [1/h]) and the mass of chemical remaining in the peritoneal cavity (MR_{ip} [mg]):

$$RA_{ip} = KA_{ip} * MR_{ip}$$

and

$$MR_{ip} = D_{ip} + \int_0^t RMR_{ip} * dt$$

where D_{ip} [mg/animal] is the actual dose of the chemical injected i.p., RMR_{ip} [mg/h] is the rate of change of the chemical remaining in the peritoneal cavity (disappearance), and t [h] is time.

It was estimated that only a small fraction of the lipophilic pro-oxidant chemical may diffuse directly to the abdominal mesenteric fat, whereas about 99% of the chemical is being absorbed to venous circulation (blood absorption ratio, $B_{ab} = 0.99$ [ratio]) and eventually drained to the portal blood and delivered to the liver. Therefore, the product of $B_{ab} * RA_{ip}$ was added to the liver compartment.

The PBPK sub-model parameters for CCl_4 , based on Paustenbach et al. (1988) and Gallo et al. (1993), were scaled allometrically to B6C3F1 mice and calibrated with data from the literature (Seckel and Byczkowski, 1996). Similarly, the PBPK sub-model parameters for TCE, based on Fisher et al. (1991), were scaled allometrically to B6C3F1 mice and calibrated with data from the literature (Das et al., 1994). The PBPK sub-model parameters for $BrCCl_3$ and TBOOH were not verified experimentally.

Classic PK Module for Intraperitoneal Dosing of Pro-Oxidant Chemicals


For many chemical compounds the PBPK sub-model parameters are not immediately available, whereas, their classic pharmacokinetic micro- and macro-constants may occasionally be found in the literature. To utilize this kind of data, an additional classic PK module was included in the pharmacokinetic sub-model and connected directly to the liver compartment. The classic PK module was based on a multiexponential equation for two-compartment system:

$$C_L = C_{L0} * k_{1,0} * (\exp(-\beta * t) - \exp(-\alpha * t)) / (\alpha - \beta)$$

where C_L is local concentration of pro-oxidant chemical [mg/kg]; C_{L0} is estimate of initial concentration of the chemical [mg/kg]; $k_{1,0}$ is pharmacokinetic transfer micro-constant [1/h]; α is pharmacokinetic macro-constant [1/hr]; and β is pharmacokinetic macro-constant [1/h]. The pharmacokinetic constants were recalculated from the literature (e.g., for CCl_4 as presented by Seckel and Byczkowski, 1996).

BBPD Module for Activation of Pro-Oxidant Chemical and Free Radical Concentration

Production of free radicals and the local concentration of pro-oxidant chemical-derived free radicals were estimated by the square root algorithm presented previously (Byczkowski and Flemming, 1996) and verified with TCE (Byczkowski et al., 1996; Channel et al., 1997). For the bioactivation and free radical quenching reactions:




it was assumed that: $d\text{FR}/dt = k_i * C_{LM} - k_t * \text{FR}_{ad} * \text{FR}_{ad} = 0$.

Therefore:

$$\text{FR}_{ad} = \sqrt{k_i * C_{LM} / k_t}$$

where FR_{ad} is a steady state concentration of pro-oxidant chemical-derived free radicals [$\mu\text{mol}/0.1$ g liver]; C_{LM} is local pro-oxidant chemical concentration [$\mu\text{mol}/0.1$ g liver]; k_i is a rate constant of free radical formation from the pro-oxidant chemical [1/h]; and k_t is the lumped rate constant of free radical recombination and quenching by the biological system [1/h].

Algorithm for CYP degradation and suicidal inhibition by activated pro-oxidant chemical was based on deterministic one-hit mechanism according to the reaction (presented previously by Byczkowski and Flemming, 1996):



it was assumed that different kinds of CYP taking part in the bioactivation of pro-oxidant chemical have uniform sensitivity to FR_{ad} .

Therefore:

$$\text{AC}_{\text{trem}} = \text{AC} * \exp(-\text{ACR} * \text{FR}_{ad} * t)$$

where AC_{trem} is concentration of active CYP remaining over time [$\mu\text{mol}/0.1 \text{ g liver}$]; AC is the initial concentration of active CYP [$\mu\text{mol}/0.1 \text{ g liver}$]; ACR is the rate constant of CYP inactivation by free radicals [$1/h$]; t is time of incubation with free radicals [h]; and FR_{ad} is a steady-state concentration of pro-oxidant chemical-derived free radicals [$\mu\text{mol}/0.1 \text{ g liver}$].

BBPD Sub-Model for Lipid Peroxidation

The BBPD sub-model estimated activity of lipid peroxidation expressed as TBARS production and ethane generation (Figure 7). The BBPD module for lipid peroxidation in the liver (calibrated with TBARS production), confirmed with experimental data for TBOOH and BrCCl_3 in precision-cut mouse liver slices, was published elsewhere by Byczkowski et al. (1996). A simplified scheme of this module is shown in Figure 7 (depicted by ovals). The source codes of *.CSL and *.CMD files for this module are archived in PBPK-L Public Domain Source Library and are accessible through the World Wide Web at the following URL: <http://www.navy.al.wpafb.af.mil/new.htm>

The PBP module for ethane exhalation (depicted by rectangles in Figure 7) was calibrated with experimental data from our laboratory (presented previously by Seckel and Byczkowski, 1996). The PBP module estimated rates of metabolism, distribution, and exhalation of ethane generated in the liver. On a molecular basis, about 0.1% of hydroperoxides derived from natural lipids will decompose to yield ethane (efficiency of ethane generation from fat, $EF_{fe} \leq 0.001$ [molar ratio]; Gardner, 1989; Janero, 1990).

BBDR Sub-Model for Cellular Target Inhibition

An inhibition of activities of cellular targets, caused by free radicals, was estimated by a biologically based dose-response (BBDR) sub-model composed of two modules, deterministic and stochastic (presented previously by Byczkowski and Flemming, 1996). This sub-model was governed by dose-dependent algorithms with time of exposure to free radicals t_p [h] fixed as a fraction (F_t [ratio]) of the time needed to reach the maximum effect (T_{me} [h]). For independent variable, the initial local concentrations of pro-oxidant chemical C_0 [μM] were increased stepwise between the estimated maximum "no effect" dose (C_{min} [μM]) and minimum "100% effect" dose (C_{max} [μM]) with the interval C_{Δ} [μM] resulting in a number of iterations "i". The initial local concentrations C_0 were captured as an array $DOSC_i$. The local, steady state concentrations of pro-oxidant chemical-derived free radicals FR_{adM} [μM] ($FR_{adM} = 10 * FR_{ad}$), at fixed time of exposure t_p [h], were captured as an array DOS_i along with initial local concentrations of pro-oxidant chemical C_0 [μM].

PBPD Sub-Model for Lipid Peroxidation




Figure 7. An interlinked biologically based pharmacodynamic (PBPD) sub-model describing lipid peroxidation combined the BBPD module for TBARS production (ovals) with the PBPD module for ethane exhalation (rectangles).

CONE - concentration of inhaled ethane [ppm]; QP - alveolar ventilation rate [L/h]; CEV - mixed venous blood ethane concentration [mg/L]; CEP - concentration of exhaled ethane [ppm]; QC - cardiac output [L/h]; CEA - concentration of ethane in arterial blood [mg/L]; QR - blood flow to rapidly perfused tissues [L/h]; QS - blood flow to slowly perfused tissues [L/h]; QF - blood flow to fat tissue [L/h]; QL - blood flow to liver tissue [L/h]; QG - blood flow through the portal vein [L/h]; CEVG - concentration of ethane in the portal vein [mg/L]; AEM - amount of metabolized ethane [mg]; CEVL - concentration of ethane in venous blood leaving the liver [mg/L]; PXREM - accumulated remaining hydroperoxides [$\mu\text{mol}/0.1 \text{ g}$]; TBARS - thiobarbituric acid reactive substances [$\mu\text{mol}/0.1 \text{ g}$]; TPX - accumulated total hydroperoxides [$\mu\text{mol}/0.1 \text{ g}$]; ANOX - vitamin E-type antioxidants [$\mu\text{mol}/0.1 \text{ g}$]; AUTOX - hydroperoxides produced by autooxidation [$\mu\text{mol}/0.1 \text{ g}$]; PUF - polyunsaturated fat [$\mu\text{mol}/0.1 \text{ g}$]; ACTIND - activated, free radical form of chemical inducer [$\mu\text{mol}/0.1 \text{ g}$]; IND1 - internal dose of chemical inducer 1 [$\mu\text{mol}/0.1 \text{ g}$]; ACR - activator (CYP) loss rate [1/h]; CL - delivered dose of pro-oxidant chemical [mg/kg].

Deterministic Module

The deterministic module estimated inhibition of uniform cellular targets (I_n [ratio]) by pro-oxidant chemical-derived free radicals (FR_{adM}) as an exponential decay function:



it was assumed that homogenous CELLULAR TARGETS have uniform sensitivity to FR_{ad} .

$$I_n = I_0 * \exp(-k_d * FR_{adM} * t_p)$$

where I_n is a remaining activity, expressed as a fraction of remaining active cellular targets, relative to the amount before inhibition [ratio]; I_0 is the initial concentration of active cellular targets, assumed to be 100% ($I_0 = 1$. [percentage/100]); k_d is the rate constant of cellular target inactivation by free radicals [100%/μM/h]; t_p is time of exposure to free radicals [h]; and FR_{adM} are the local, steady state concentrations of pro-oxidant chemical-derived free radicals [μM]. The values of the remaining relative activity I_n were captured as an array I_{nh} :

$$I_{nh} = [I_{n1}, I_{n2}, \dots I_{ni}].$$

Stochastic Module

The stochastic module estimated inhibition of non-uniform cellular targets (PROB [ratio]) by exposure for time t_p [h] to pro-oxidant chemical-derived free radicals (array DOS) as a 1 minus time-weighted fraction of a cumulative Gaussian distribution function:



it was assumed that non-uniform MULTIPLE TARGETS give normal distribution of the INHIBITORY RESPONSES to FR_{ad} .

$$PROB = 1 - F_t * \int_{-\infty}^x \frac{1}{\sqrt{2\pi}} * \exp(-z^2/2) * dz$$

where $x = (DOS - M)/SD$; PROB is probability of cellular targets to remain active, relative to the amount before inhibition (expressed as a fraction of remaining active cellular targets, relative to the amount before inhibition [ratio]); DOS is array of free radical concentration values [μM], generated during exposure to the range of concentrations of pro-oxidant chemical (between maximum “no effect” and minimum “100% effect” doses); F_t is as a fraction [ratio] of the time needed to reach the maximum effect ($F_t = t_p/T_{me}$); M is mean of the cumulative Gaussian distribution of free

radical concentration values [μM]; SD is standard deviation of the cumulative Gaussian distribution of free radical concentration values [μM]; and z is a variable of integration.

PARAMETRIZATION AND CALIBRATION OF SUB-MODELS WITH DATA

PBPK Sub-Model for Internal Dose of Pro-Oxidant Chemical

Chemical-dependent parameters for TCE PBPK module in B6C3F1 mice (confirmed with data from Fisher et al., 1991) were presented previously by Das et al. (1994), and those parameters for CCl_4 (confirmed with data from Sanzgiri et al., 1995; Gallo et al., 1993; Gargas et al., 1986; and Paustenbach et al., 1986; 1988), scaled to B6C3F1 mice, were presented previously by Seckel and Byczkowski (1996). These parameters, optimized with SIMUSOLV®, are listed in Table 1. The animal-specific PBPK modeling parameters were as recommended by ILSI, RSI (1994) for mice.

TABLE 1. CHEMICAL-SPECIFIC PHARMACOKINETIC PARAMETERS FOR TCE AND CCl_4 IN B6C3F1 MICE

Parameter	Description	TCE	CCl_4
Partition coefficients [ratio]			
PBC	Blood/air	13.4 ^e	4.52 ^a
PLC	Liver/blood	2.03 ^e	3.14 ^a
PFC	Fat/blood	41.3 ^e	79.4 ^a
PRC	Rapidly perfused tissue/blood	2.03 ^e	3.14 ^a
PSC	Slowly perfused tissue/blood	1.0 ^e	2.43 ^b
Molecular weight [g/mol]			
MW		131.5	153.82
Metabolism constants			
VMAXC	Maximum velocity [mg/hr/kg]	33.0 ^e	0.65 ^c
KM	Michaelis-Menten constant [mg/L]	0.25 ^e	0.25 ^c
KFC	1st order rate constant [1/hr/kg]	2.4 ^e	0.0 ^c
Absorption rate [1/hr]			
KAIP	First order i.p. uptake	1.0 ^d	1.45 ^d
Pharmacokinetic transfer constants fitted [1/hr]			
k10	Micro-constant	0.03 ^d	0.3 ^d
α	Macro-constant	0.01 ^d	1.5 ^d
β	Macro-constant	2.0 ^d	1.6 ^d

^a from Gargas (1988).

^b from Evans et al. (1994).

^c from Gargas et al. (1986)

^d from Seckel and Byczkowski (1996).


^e from Das et al. (1994).

Classic PK Module for Intraperitoneal Dosing of Pro-Oxidant Chemicals

The pharmacokinetic micro- and macro-constants [1/h] were fitted to data from our laboratory obtained with B6C3F1 mice treated i.p. with TCE and CCl₄ (Seckel and Byczkowski, 1996). The pharmacokinetic transfer constants for classic PK module are listed in Table 1.

BBPD Module for Activation of Pro-Oxidant Chemical and Free Radical Concentration

Two algorithms describing the relationship between steady-state concentration of free radicals and local TCE concentration were tested, the square root algorithm (assuming that two free radicals are formed from one molecule of TCE, as described above) and a linear algorithm (Byczkowski et al., 1996; Channel et al., 1997). The linear algorithm described the reaction in which one free radical is formed from one molecule of TCE:



Assuming steady state concentrations of free radicals: $d\text{FR}/dt = k_i * C_{\text{LM}} - k_t * \text{FR}_{\text{ad}} = 0$,

$$\text{FR}_{\text{ad}} = k_i * C_{\text{LM}} / k_t$$

where FR_{ad} is a steady-state concentration of TCE-derived free radicals [$\mu\text{mol}/0.1 \text{ g liver}$]; C_{LM} is local TCE concentration [$\mu\text{mol}/0.1 \text{ g liver}$]; k_i is a rate constant of free radical formation from TCE [1/h]; and k_t is the lumped rate constant of free radical recombination and quenching by the biological system [1/h].

Quantitative measurements of FR_{ad} *in vitro* using an EPR-spin trapping method failed to confirm either algorithm (Figure 8). Despite a relatively large variability in time-dependent measurements of TBARS produced in liver slices incubated with TCE (Figure 9), the dose-dependent data were much better fitted with the square root algorithm (Figure 10, curve B) than with the linear algorithm (Figure 10, curve A). Thus, the quantitative measurements of TBARS *in vitro* confirmed an adequate description of the relationship between concentration of free radicals and local TCE concentration by the square root algorithm (Byczkowski et al., 1996; Channel et al., 1997).

BBPD Sub-Model for Lipid Peroxidation

As the square root algorithm and the time-dependent activator degradation equation were introduced into the BBPD module for lipid peroxidation in the liver (originally calibrated as a linear algorithm with the experimental data from precision-cut mouse liver slices with TBOOH and BrCCl₃, Byczkowski et al., 1996), the modeling parameters had to be recalculated and optimized

with SIMUSOLV® software. All optimized parameters added or changed from those originally published by Byczkowski et al. (1996) are listed in Table 2. The chemical-specific parameters (factors ACTDGF and PTIND) were estimated and optimized for a range of concentrations for TCE (0.4 - 5.6 $\mu\text{mol}/0.1 \text{ g liver}$) and CCl_4 (0.5 - 7.6 $\mu\text{mol}/0.1 \text{ g liver}$).

BBPD Module: Effect of TCE on Generation of Free Radicals




Figure 8. Calibration of the algorithm describing concentration of free radicals under steady-state conditions (FRAD [$\mu\text{mol/g}$]) with experimental data from Steel-Goodwin et al. (1995) for free radical generation by different concentrations of TCE [$\mu\text{mol}/0.1 \text{ g liver}$] in mouse liver slices using an EPR/spin-trapping method.

FRAD -concentration of PBN-reactive free radicals [$\mu\text{mol/g liver}$]. The squares represent actual average experimental data points (after subtraction of physiological background levels of free radicals produced in the absence of TCE). The continuous lines are computer-generated simulations involving: A - linear algorithm; B - square root algorithm.

Since the original BBPD sub-model for lipid peroxidation was calibrated with BrCCl_3 (Tappel et al., 1989; Byczkowski et al., 1996), we have used the same well known pro-oxidant chemical to check if it will lead to a measurable lipid peroxidation at comparable local concentrations both *in vitro* and *in vivo*.

BBPD Module: Effects of TCE on Lipid Peroxidation




Figure 9. Results of time-dependent simulation of lipid peroxidation in mouse liver slices induced by 1 mM TCE. TBARS - thiobarbituric acid reactive substance $\times 10^{-3}$ [mmol/0.1 g liver]. Small squares depict average experimental data from our laboratory ($n=4$) described by Byczkowski et al. (1996). The continuous lines depict computer simulations with BBPD sub-model involving the square root algorithm and parameters optimized by SIMUSOLV® software (listed in Table 2), amount of TBARS at time=0 was subtracted from the data.

TABLE 2. PHARMACODYNAMIC PARAMETERS FOR TCE AND CCl_4 IN B6C3F1 MICE

Parameter	Description	Optimized numerical value
Factors [$1/\mu\text{mol}$]		
ACTDGF1	Activator degradation factor 1 (TCE)	0.0014
ACTDGF2	Activator degradation factor 2 (CCl_4)	1.75
PTIND1	Potency of inducer 1 (TCE)	250.
PTIND2	Potency of inducer 2 (CCl_4)	4408.
Rate constants [$1/\text{h}$]		
AUTOXF	Autooxidation rate	0.00013
PXREDF	Hydroperoxide reduction rate	0.17
ACR	Activator degradation rate	0.025
INDLF	Inducer loss rate	0.0001

BBPD Module: Effects of TCE on Lipid Peroxidation




Figure 10. The results of dose-dependent simulations of lipid peroxidation in mouse liver slices for 0.5 h induced by different concentrations of TCE [$\mu\text{mol}/0.1 \text{ g liver}$]. TBARS - thiobarbituric acid reactive substance $\times 10^{-3}$ [$\text{mmole}/0.1 \text{ g liver}$]. Small squares depict average experimental data from our laboratory ($n=4$). Lines depict computer simulations with BBPD sub-model involving: A - linear algorithm (PTIND1=6.9); B - square root algorithm (PTIND1=250). The other parameters were optimized by SIMUSOLV® software. Amounts of TBARS in untreated controls were subtracted from the data (Byczkowski et al., 1996).

Bromotrichloromethane stimulated TBARS generation by precision-cut mouse liver slices *in vitro* (Figure 11). The lowest measurable effect was noticed at 0.1 mM BrCCl_3 in the medium. Considering its partition coefficients (medium/air = 2, and liver/air = 29), the 100 μM BrCCl_3 could produce an initial concentration of 0.145 $\mu\text{mol}/0.1 \text{ g liver}$. The dose-response curves had a characteristic sigmoidal shape with a plateau reached at about 1 mM BrCCl_3 , when incubated for 0.5 h, and at about 0.5 mM BrCCl_3 when incubated for 1 h. A prolonged incubation (above 1 h) with higher than 0.5 mM concentrations of BrCCl_3 failed to increase further the rate of TBARS generation by liver slices (results not shown here).

Figure 12 shows the results of measurement of ethane exhalation by mice in a closed gas chamber. The treatment with BrCCl_3 at a dose above 0.025 g/kg resulted in increased ethane exhalation measured 1h after the exposure. Twice as high dose was required to produce a significant increase in ethane exhalation after 0.5 h from the exposure. Again, the dose-response curves had a sigmoidal shape.




Figure 11. Effects of different doses of BrCCl₃ (concentration in the medium [mM]) on production of thiobarbituric acid reactive substances (TBARS - thiobarbituric acid reactive substance x 10⁻³ [mmole/0.1 g liver]) by mouse liver slices incubated for either 0.5 or 1 h in the presence of inducer.

The respective background values were subtracted from data points. Background production of TBARS in controls were respectively: 0.0226 μ mole/g liver ($\pm$ 0.0025 S.D., n=4) at 0.5 h, and 0.0303 μ mole/g liver ($\pm$ 0.0035 S.D., n=4) at 1 h. Data points were significantly different from the corresponding controls (at $p \leq 0.05$, n=4) by Student's t-test.

Figure 13 shows actual time courses of stimulated ethane exhalation by mice treated with four different doses of BrCCl₃ (0.025, 0.05, 0.1, and 1.0 g/kg). The reliable ethane quantification threshold was 0.025 ppm. There was no significant difference between ethane exhalation (followed for up to 2 h) in mice before and after i.p. injection of 0.2 mL of mineral oil only (by one-way Anova at $p \geq 0.05$).

Effect of BrCCl₃ on Ethane Exhalation




Figure 12. Effects of different doses of BrCCl₃ (injected i.p. [g/kg]) on ethane exhalation by five mice during either 0.5 or 1 h from the exposure to inducer (Ethane - concentration in the chamber [ppm]).

The respective physiological ethane exhalation values (background) from the same group of five mice, measured before treatment, were subtracted from the data points (respectively, 0.0435 ppm [± 0.022 S.D., $n=5$] at 0.5 h, and 0.0447 ppm [± 0.020 S.D., $n=4$] at 1 h).

Verification of BBPD Sub-Model for Lipid Peroxidation in vitro

The BBPD module of lipid peroxidation sub-model was further verified with *in vitro* effects of CCl₄ on the generation of TBARS by precision-cut mouse liver slices (Figure 14). The parameters were optimized with SIMUSOLV® to satisfy all set (time- and dose-dependent) of experimental data.

Verification of BBPD Sub-Model for Lipid Peroxidation in vivo

Based on the “upside down” PBPK model for ethane distribution (input in the liver, output in the lung), a PBPD module for ethane exhalation was constructed, assuming that the production of reactive free radical metabolites of xenobiotics takes place in the liver (Figure 7). At first, the module was calibrated with data from mice *in vivo*, inhaling a known concentration of ethane in a closed gas chamber (Figure 15 presented previously by Seckel and Byczkowski, 1996). These calibrations allowed us to verify partition coefficients of ethane and to estimate metabolism constants (V_{mexc} , K_{em} , and K_{efc}). Pharmacokinetic parameters for ethane exhalation module are listed in Table 3.

Time-Dependent Effects of BrCCl₃ on Ethane Exhalation




Figure 13. Time-course of effects of four different doses of BrCCl₃ (injected i.p. [g/kg]) on ethane exhalation (concentration in the chamber [ppm]) by five mice. The respective physiological ethane exhalation values (background) from the same group of five mice, measured before treatment, were subtracted from the data points. The horizontal line depicts a reliable detection level of ethane by the method used (detectability threshold + 2 SD). The ethane exhalation time courses after exposure to 0.05 (after 1 h but not 0.5 h), 0.1 and 1.0 g BrCCl₃/kg were significantly different from the corresponding control curves before treatment (by one-way Anova at $p \leq 0.05$). Other details are the same as in Figure 12.

Next, the PBDP sub-model, including the module for ethane exhalation, was tested *versus* experimental data from mice treated *in vivo* with TCE (Figure 16). The square root algorithm was included in the BBPD module for free radical concentration and the PBDP sub-model simulated time-dependent effects of different doses of TCE on ethane exhalation in B6C3F1 mice *in vivo* (Figure 16). The reliable ethane quantification threshold was 0.025 ppm.

BBPD Module: Effects of CCl₄ on Lipid Peroxidation




Figure 14. Time-dependent effects of four concentrations of CCl₄ (□-0.1, ▣-0.5, ■-1.0, and ■-1.5 mM) on TBARS generation by precision-cut mouse liver slices *in vitro*. Lines are computer-generated simulations by the lipid peroxidation sub-model (optimized parameters: PTIND1=4408; ACR=0.025; other parameters the same as in Table 2).

TABLE 3. PHARMACOKINETIC PARAMETERS FOR ETHANE EXHALATION IN B6C3F1 MICE

Parameter	Description	Numerical value
Partition coefficients [ratio]		
PLA	Liver/air	0.828
PGA	Gut/air	0.996
PFA	Fat/air	2.444
PSA	Slowly perfused tissue/air	0.979
PRA	Richly perfused tissue/air	0.996
PEB	Blood/air	1.305
Molecular weight [g/mol]		
MW		30.0
Optimized metabolism constants		
VMEXC	Maximum velocity [mg/hr/kg]	0.286
KEM	Michaelis-Menten constant [mg/L]	0.51
KEFC	1st order rate constant [1/hr/kg]	2.786
EFFE	Efficiency of ethane generation [molar ratio]	0.001

Data presented previously by Seckel and Byczkowski (1996).




Figure 15. The results of PBPD sub-model simulations of our experimental data from mice inhaling ethane in a closed chamber (initial concentration of ethane 1 ppm). CEP - Concentration of ethane in a closed chamber [ppm]; Time - [h]. Symbols depict experimental data collected from the closed chamber (four animals per time-point); continuous line is the PBPD model simulation (Seckel and Byczkowski, 1996).

At this step, the yield of ethane generation from lipid hydroperoxides was estimated ($EF_{fe} = 0.001$ [molar ratio]) by comparing the simulated molar amounts of ethane *in vivo* (Figure 16) with TBARS *in vitro* (Figure 10), produced in response to the same total cumulated dose (area under the concentration curve, AUC) of TCE in the liver.

Finally, the calibrated PBPD sub-model was verified with our data for ethane exhalation, induced by four different doses of carbon tetrachloride (CCl_4 -specific parameters were taken from our *in vitro* calibration, Figure 14). At this verification step, the parameters estimated during the *in vivo* calibration with TCE were not further adjusted. Figure 17 shows the time-dependent effects of four different doses of CCl_4 on ethane exhalation along with the computer-generated simulations by the BBPD sub-model. The dose-dependent effects of CCl_4 on ethane exhalation and the computer-generated simulations at three different times from treatment are presented in Figure 18.

PBPD: Effects of TCE on Ethane Exhalation in Mice




Figure 16. The results of PBPD model simulations of our experimental data from mice treated i.p. with three different doses of TCE ($\square$ -0.26, $\blacksquare$ -1.0, and $\blacksquare$ -2.6 g/kg) and exhaling ethane in a closed chamber (Byczkowski et al., 1996).

CEP - concentration of ethane in a closed chamber [ppm]; Time - [h]. Symbols depict experimental data collected from the closed chamber (five animals per time-point) with the respective physiological ethane exhalation values (background) from the same group of five mice, measured before treatment, subtracted from the data points. Lines are the PBPD model simulations. The horizontal line depicts a reliable ethane quantification threshold by the method used (detectability threshold + 2 S.D.). Inset shows PBPK sub-model simulations of local TCE concentrations in the liver. CL - local concentration [mg/kg liver]; T - time [h].

BBDR Sub-Model for Cellular Target Inhibition

Two modules, composing the BBDR sub-model for cellular target inhibition by pro-oxidant chemical-derived free radicals, were based on either deterministic or stochastic equation, respectively, and were calibrated with *in vitro* data from the literature (Byczkowski and Flemming, 1996).

Deterministic Module

The deterministic BBDR module was calibrated with experimental data of Vroegop et al., (1995) for inhibition of amino acid and glucose transporters in N 18 neuronal hybridoma cell line in culture, incubated with cumene hydroperoxide (Figure 19 A) or hydrogen peroxide (Figure 19 B),

PBPD: Effects of CCl_4 on Ethane Exhalation by Mice In Vivo




Figure 17. Time-dependent effects of four different doses of CCl_4 i.p. on the concentration of ethane exhaled by mice in a closed gas chamber *in vivo* (A. $\square$ -0.075, B. $\blacksquare$ -0.15, C. $\blacksquare$ -0.3, and D. $\blacksquare$ -1.5 g/kg).

Lines are computer-generated simulations by the ethane exhalation BBPD sub-model (parameters that describe lipid peroxidation were the same as in Table 3). The respective physiological ethane exhalation values (background) from the same groups of five mice, measured before treatment, were subtracted from the data points. The reliable ethane quantification threshold by the method used was 0.025 p.p.m. (detectability threshold + 2 SD).

respectively, Heffetz et al. (1990), and Hecht and Zick (1992), for inhibition of protein tyrosine phosphatase (PTyrPase) in rat hepatoma cells in culture incubated with hydrogen peroxide (Figure 19 C) or vanadate (Figure 19 D), respectively. The rate constant for quenching of free radicals by all biological systems investigated (k_t [1/ $\mu\text{M}/\text{h}$]) was estimated as 200.0 [1/ $\mu\text{M}/\text{h}$] and was fixed during all simulations. Rate constants of free radical formation (k_i [1/ $\mu\text{M}/\text{h}$]) were chemical-specific and rate constants of cellular target inhibition [1/ $\mu\text{M}/\text{h}$] were biological system-specific, and they were optimized with SIMUSOLV® software. Initial concentrations of active targets were assumed to be 100% in uninhibited biological systems before incubation with pro-oxidant chemicals ($I_0 = 1.0$ [%/100]). Timing parameters [h] were dependent on experimental setup. The

final simulation parameters are listed in Table 4, as presented previously by Byczkowski and Flemming (1996).

**BBPD Model: Dose-Dependent Effects of CCl₄ on Ethane
Exhalation by Mice In Vivo**




Figure 18. Dose-dependent effects of CCl₄ i.p. on the concentration of ethane exhaled by mice in a closed gas chamber *in vivo*, measured at three different times from treatment (□-0.33, ■-0.75, and ■-1.0 h).

Lines (A, B, and C) are computer-generated simulations by the ethane exhalation BBPD sub-model (parameters that describe lipid peroxidation were the same as in Table 3). The respective physiological ethane exhalation values (background) from the same groups of five mice, measured before treatment, were subtracted from the data points. The reliable ethane quantification threshold by the method used was 0.025 ppm (detectability threshold + 2 SD).

Stochastic Module

The stochastic BBDR module was calibrated with experimental data of Vroegop et al. (1995) for inhibition of amino acid transporter and mitochondrial activity in N 18 neuronal hybridoma cell line in culture, incubated with 6-OH dopamine (Figure 20 A, C) or hydrogen peroxide (Figure 20 B, D), respectively. Optimized simulation parameters are listed in Table 4, as presented previously by Byczkowski and Flemming (1996).

Some data from the literature covered a dose-response characteristics of the wide range of pro-oxidant chemical concentrations, especially when the response kinetics was slow. For such data sets, to discriminate between the targeted and random hit mechanisms using the BBDR sub-model,

it was necessary to express the pro-oxidant chemical concentrations on a logarithmic scale rather than on a linear one (Figure 21).




Figure 19. Calibration of the deterministic BBDR module with *in vitro* data for inhibition of cellular targets by free radicals generated by pro-oxidant chemicals. Lines are computer-generated simulations by the deterministic BBDR module. Black squares depict data from the literature. Insets show, for comparison, simulations by the stochastic BBDR module (curves depicted by empty squares) with the same data (black squares).

Optimized parameters are listed in Table 4.

A. Effects of different concentrations of cumene hydroperoxide (Cum.OOH [μ M]) on activity of amino acid (AA) transporter in N 18 neuronal hybridoma cell line in culture (INH [ratio]) after 1 h (*plus* 1 h preincubation with Cum.OOH; data points from Vroegop et al., 1995). B. Effects of different concentrations of hydrogen peroxide (H₂O₂ [μ M]) on activity of glucose transporter (Gluc) in N 18 neuronal hybridoma cell line in culture (INH [ratio]), after 1 h (*plus* 1 h preincubation with H₂O₂; data points from Vroegop et al., 1995). C. Effects of different concentrations of hydrogen peroxide (H₂O₂ [μ M]) on activity of protein tyrosine phosphatase (PTyrPase) in rat hepatoma cells in culture (INH [ratio]) after 5 min (*plus* 20 min preincubation with H₂O₂; data points from Heffetz et al., 1990). D. Effects of different concentrations of vanadate (Vanad [μ M]) on activity of protein tyrosine phosphatase (PTyrPase) in rat hepatoma cells in culture (INH [ratio]), after 8 min (*plus* 0.5 h preincubation with vanadate; data from Hecht and Zick, 1992).

TABLE 4. PARAMETERS FOR THE BIOLOGICALLY BASED PHARMACODYNAMIC MODEL DESCRIBING THE INHIBITION OF CELLULAR TARGETS BY CHEMICALLY GENERATED FREE RADICALS

Parameter	Description	Numerical value
Rate constants of FR formation [1/ μ M/h]		
ki	from Cum.OOH	100.0 ^a
ki	from 6OHD	200.0 ^a
ki	from H ₂ O ₂ , vanadate and pervanadate	18.0 ^{a,f}
ki	from TCE	900.0 ^b
Rate constant of FR quenching [1/ μ M/h]		
kt	fixed for all biological systems	200.0 ^c
Rate constants of cellular target inhibition [1/ μ M/h]		
kd	AA transporter	0.075 ^a
kd	mitochondria	0.05 ^a
kd	Gluc. transporter	0.1 ^a
kd	PTyrPase	1.0 ^f
Initial concentration of active targets [%/100]		
I0	assumed value for all biological systems	1.0
Time of pre-incubation with FR [h]		
tp	Fig 19 A - B	1.0 ^d
tp	Fig. 8 B	0.333 ^e
tp	Fig. 19 D	0.5 ^g
tp	Fig. 19 C	0.333 ^h
Length of experiment [h]		
TSTOP	Fig. 19 A - B	2.0 ^d
TSTOP	Fig. 8 B	0.333 ^e
TSTOP	Fig. 19 D	0.633 ^g
TSTOP	Fig. 19 C	0.42 ^h

Abbreviations: Cum.OOH - cumyl hydroperoxide; 6-OHD - 6-hydroxy dopamine; TCE - trichloroethylene; FR - free radicals; AA - amino acids; Gluc. - glucose; PTyrPase - protein tyrosine phosphatase.

^a fitted to Vroegop et al. (1995).

^b fitted to Steel-Goodwin et al. (1995).

^c estimated from Vroegop et al. (1995), Steel-Goodwin et al. (1995), Heffez et al. (1990), and Hecht and Zick (1992).

^d experimental from Vroegop et al. (1995).

^e experimental from Steel-Goodwin et al. (1995).

^f fitted to Heffez et al. (1990) and Hecht and Zick (1992).

^g experimental from Hecht and Zick (1992).

^h experimental from Heffez et al. (1990).




Figure 20. Calibration of the stochastic BBDR module with *in vitro* data for inhibition of cellular targets by free radicals generated by pro-oxidant chemicals. Curves depicted by empty squares are computer-generated simulations by the stochastic BBDR module. Black squares depict data from the literature. Insets show, for comparison, simulations by the deterministic BBDR module (lines) with the same data (black squares). Optimized parameters are listed in Table 4.

A. Effects of different concentrations of 6-hydroxy dopamine (6-OH Dopamine [μM]) on activity of amino acid (AA) transporter in N 18 neuronal hybridoma cell line in culture (PROB [ratio]), after 1 hour (*plus* 1 h preincubation with 6-OH dopamine; data points from Vroegop et al., 1995). B. Effects of different concentrations of hydrogen peroxide (H_2O_2 [μM]) on activity of amino acid transporter (AA) in N 18 neuronal hybridoma cell line in culture (PROB [ratio]), after 1 hour (*plus* 1 h preincubation with H_2O_2 ; data points from Vroegop et al., 1995). C. Effects of different concentrations of on activity of mitochondrial reduction of MTT (Mitochondria) in N 18 neuronal hybridoma cell line in culture (PROB [ratio]), after 1 hour (*plus* 1 hr preincubation with 6OHD; data points from Vroegop et al., 1995). D. Effects of different concentrations of hydrogen peroxide (H_2O_2 [μM]) on mitochondrial reduction of MTT (Mito) in N 18 neuronal hybridoma cell line in culture (PROB [ratio]), after 1 hour (*plus* 1 hr preincubation with H_2O_2 ; data points from Vroegop et al., 1995).

For some data of Vroegop et al. (1995), the simulations with BBDR sub-model could not distinguish between the targeted or random hit mechanisms, and both deterministic and stochastic BBDR modules gave an equal “goodness of fit” (Figure 22).




Figure 21. Calibration of the BBPD sub-model with *in vitro* data for inhibition of cellular targets by free radicals generated by pro-oxidant chemicals. Lines are computer-generated simulations by the deterministic BBDR module (A) whereas curves depicted by empty squares are computer-generated simulations by the stochastic BBDR module (B). Black squares depict data from the literature. Insets show, for comparison, simulations by either stochastic (A) or deterministic (B) BBDR modules, with the same data (black squares). Optimized parameters are listed in Table 4.

A. Effects of different concentrations of pervanadate (Pervan. [Log μM]) on the activity of protein tyrosine phosphatase (PTyrPase) in rat hepatoma cells in culture (INH [ratio]), after 15 min (*plus* 0.5 h preincubation with Pervan.; data points from Heffez et al., 1990). B. Effects of different concentrations of cumene hydroperoxide (Cum.OOH [Log μM]) on activity of mitochondrial reduction of MTT (Mitochondria) in N 18 neuronal hybridoma cell line in culture (PROB [ratio]), after 1 h (*plus* 1 h preincubation with 6OHD; data points from Vroegop et al., 1995). Optimized parameters are listed in Table 4.




Figure 22. Calibration of the BBPD sub-model with effects of different concentrations of cumene hydroperoxide (PCONC [μM Cum.OOH]) on activity of glucose transporter (GLU) in N 18 neuronal hybridoma cell line in culture (INH [ratio]), after 1 h (*plus* 1 h preincubation with Cum.OOH; data points from Vroegop et al., 1995).

The continuous line is a computer-generated simulation by the deterministic BBDR module. Black squares depict data from the literature. Insets show, for comparison, a simulation by the stochastic BBDR module (the curve depicted by empty squares) with the same data (black squares). Optimized parameters are listed in Table 4.

DISCUSSION

PBPD MODEL

Several mathematical models of lipid peroxidation and free radical reactions leading to the oxidative stress were developed and described in the literature (Babbs and Steiner, 1990; Suzuki and Ford, 1994; Antunes et al., 1994; Vroegop et al., 1995). However, none of these models could be applied for dose-response characterization of pro-oxidant chemicals *in vivo*. The purpose of this modeling effort was to provide a quantitative tool, based on biochemical mechanisms, capable of predicting the biological effects of pro-oxidant chemicals (Figure 23).




Figure 23. A scheme of PBPD model of chemically induced oxidative stress. For verification of the quantitative PBPD time- and dose-response model for pro-oxidant chemicals, a continuously responding end-point was measured as a biomarker (lipid peroxidation which generates TBARS and ethane).

PBPK - physiologically based pharmacokinetic sub-model; BBPD - biologically based pharmacodynamic sub-model; PBPD - physiologically based pharmacodynamic module; BBDR - biologically based dose-response sub-model.

The resultant PBPD model of chemically induced oxidative stress, consisting of three sub-models (PBPK/PK, BBPD, BBDR) and a PBPD module for ethane exhalation, may be used to predict time- and dose-response of biological systems, both *in vitro* and *in vivo*, to pro-oxidant chemicals, such as volatile chlorinated hydrocarbons (e.g., TCE, CCl_4 , or $BrCCl_3$).

Several crucial assumptions were made during the construction of this PBPD model. The PBPK sub-model was built assuming the blood-flow limited delivery of pro-oxidant chemicals (Evans and Andersen, 1995; Kedderis, 1996). This was justified in the case of volatile chlorinated hydrocarbon solvents (Fisher et al., 1991; Gallo et al., 1993; Gargas et al., 1986; Paustenbach et al., 1988), and if needed, the sub-model may be expanded with algorithms involving "diffusion coefficients" for diffusion-limited chemicals (e.g., xenobiotics similar to dioxin; Kohn et al., 1993). The PBPK sub-model may be fitted with other sets of chemical-specific parameters and may be scaled allometrically to simulate local delivery of the pro-oxidant chemical in different animal species (Yang and Andersen, 1994). The PK module can accept pharmacokinetic macro- and micro-constants for two-compartment classical model.

The BBPD sub-model was built on a template of a previously published mathematical model for chemically induced lipid peroxidation in precision-cut liver slices (Byczkowski et al., 1996), assuming a steady-state concentration of pro-oxidant chemical-derived free radicals in the liver over time at each dose level. This assumption does not hold during the initial phase of free radical generation/mixing and during the terminal phase of free radical metabolism/quenching (Figure 24 A) and, therefore, it could not be used for rapid pulses of free radicals. On the other hand, under experimental conditions, the free radical reactions and diffusion rates are very fast (Antunes et al., 1994), so the equilibrium in the biological system is achieved almost instantaneously and, thus, the steady-state approximation gave satisfactory estimates of free radical biological effects in cellular systems (McKenna et al., 1991; Vroegop et al., 1995). Consequently, the local dose of free radicals in the liver was considered as an array (DOS) of sustained steady-state concentrations over time at each pro-oxidant chemical delivered dose (Figure 24 B) ignoring both the initial and the terminal phase (assumed a set of "zero order" functions of FR over time; Figure 24).




Figure 24. Representations of: A. a steady state concentration of pro-oxidant chemical-derived free radicals (FR_{ad}). B. an array (DOS) of the steady state concentrations of pro-oxidant chemical-derived free radicals (FR_{ad}).

The PBPD module was built as an "upside down" PBPK model for a volatile compound (ethane), assuming its production in the liver only, and the blood-flow limited redistribution (Seckel and Byczkowski, 1996). Obviously, other metabolically competent organs may also generate free radicals from pro-oxidant chemicals and contribute to the ethane production, but since the liver is the most active metabolically (Kulkarni and Byczkowski, 1994a), its contribution is overwhelming.

Once the maximum no-effect concentration of pro-oxidant chemical in the liver (C_{min}) and minimum 100% effective concentration (C_{max}) have been estimated (along with the time needed to accomplish the maximum effect, T_{me}) using the PBPK and BBPD sub-models, the BBDR sub-model was used to simulate and predict the dose-dependent inhibitions of cellular targets. Because in the BBDR sub-model, delivered doses of pro-oxidant chemical in the liver (expressed as initial concentrations, C_0) were set as a discrete variable (with an interval C_{Δ}), the corresponding steady-state concentrations of free radicals over time were returned by the model as an array (DOS; Figure 24 B). Considering the two possible modes of action of free radicals on cellular targets, deterministic or stochastic, the frequency of hitting targets depended on specificity and homogeneity of interactions (Figure 25). Thus, in the deterministic mode, a specific "shooting" of uniformly susceptible targets by free radicals in a homogenous phase gave a number of interactions (effective hits) proportional to the number of free radicals (Figure 25 A).




Figure 25. Representations of interaction between: A. steady state concentrations of free radicals (FR_{ad}) and homogenous cellular targets. B. arrays (DOS) of the steady-state concentrations of free radicals and heterogenous cellular targets.

On the other hand, in the stochastic mode, a random “shooting” of differently susceptible targets by free radicals in non-homogenous phases, gave a bell-shape distribution curve of the number of interactions (effective hits) over the arrays of free radicals (Figure 25 B). Assuming that this is a normal distribution, an algorithm for a 1 *minus* cumulative Gaussian distribution function was used in the stochastic module to predict the fraction of remaining active cellular targets, after Vroegop et al. (1995). These assumptions made it possible to distinguish between a specific inhibition of enzymatic or transporting cellular activities (e.g., protein tyrosine phosphatase activity by H_2O_2 -derived free radicals; Figure 19 C) and a non-specific inhibition (e.g., mitochondrial reduction of MTT activity by H_2O_2 -derived free radicals; Figure 20 D), based on the shape of a dose-response curve fitted to the experimental data.

OXIDATIVE STRESS AND LIPID PEROXIDATION

Pro-oxidant chemicals are bioactivated by CYP (mainly in the liver) to metabolites producing free radicals and initiating lipid peroxidation (Larson and Bull, 1992; Cojocel et al., 1989; Rosen and Rauckman, 1982; Poyer et al., 1978; Burdino et al., 1973). Our EPR spin-trapping study of mouse liver treated *in vitro* with pro-oxidant chemicals confirmed the increased production of free radicals (Steel-Goodwin et al., 1996), but an attempt to use the EPR signal as a quantitative end point to calibrate the production of free radicals from TCE turned to be unsuccessful (Figure 8). On the other hand, TBARS production in the liver was found to be a convenient quantitative end point, following the free radical generation (Figure 10) and lipid peroxidation, and thus, it was used as a biomarker for PBPD model calibrations *in vitro* (Figures 9, 11, and 14).

Riely et al., (1974) have demonstrated that chlorinated hydrocarbons, such as CCl_4 , increase ethane exhalation by mice due to lipid peroxidation *in vivo*. Ethane exhalation by animals treated with CCl_4 was enhanced by pretreatment with phenobarbital and suppressed by α -tocopherol (vitamin E), and it was suggested that the formation of carbon trichloromethyl free radical ($\text{CCl}_3^\bullet$) by CYP in the liver was responsible for initiation of lipid peroxidation (Riely et al., 1974). Bromotrichloromethane, another pro-oxidant chemical from which CYP generates $\text{CCl}_3^\bullet$, increased ethane exhalation in rats, especially in vitamin E- and selenium-deficient group (Burk and Lane, 1979). However, the same authors postulated also that CCl_4 - and BrCCl_3 -induced lipid peroxidation does not necessarily correlate with liver necrosis, and may be involved at an early stage of hepatotoxicity (Burk and Lane, 1979). Since then, the ethane exhalation test was proved to be a reliable, non-invasive index of oxidative stress in experimental animals and humans (Jeejeebhoy, 1991; Kneepkens et al., 1994), and thus, we used it as a biomarker for PBPD model calibrations *in vivo* (Figures 12, 13, 16, 17, and 18).

On the other hand, despite causing lipid peroxidation as a relatively early event, oxidative stress may actually stimulate cellular proliferation, induce apoptosis, and at a very high dose of pro-oxidant chemical, it may cause necrosis (Byczkowski and Kulkarni, 1996). Some of these biological effects seemed to be mediated by latching into the cellular signal transduction process (Byczkowski and Channel, 1996). Because chemically induced oxidative stress depends on a dose of pro-oxidant chemical, it seemed essential in our study to follow effects of a range of doses of pro-oxidant chemicals on lipid peroxidation (Figures 13, 16, and 17) rather than to check only a time-course at one effective dose, as some other authors have done (Riely et al., 1974; Burk and Lane, 1979).

Comparison of Pro-Oxidant Chemical Concentrations *in vitro* vs. *in vivo*:

Since the original mathematical model for lipid peroxidation was calibrated with BrCCl_3 *in vitro* (Tappel et al., 1989), we used the same compound to compare a feasibility of measuring the biomarkers in our biological systems both *in vitro* (Figure 11) and *in vivo* (Figure 12), with a similar range of the pro-oxidant chemical dosage. Assuming that about 99% of the 1 g/kg of BrCCl_3 injected i.p., at the highest dose level, will eventually pass through the liver *in vivo*, the total cumulated internal dose (AUC) was estimated as about 2 mg/0.1 g liver over 4 h (or 10 μmol /0.1 g liver/4 h), equivalent to about 2.5 μmol /0.1 g liver/h. This amount would be compatible with the initial concentration of 0.145 to 2.175 μmol /0.1 g liver used *in vitro* (Figure 11). However, even though BrCCl_3 partitions preferentially in the blood, its peak concentration in the liver venous blood after the highest dose used reached only about 0.2 mg/L or 1 μM

concentration. Considering the liver/blood partitioning of BrCCl_3 (0.7), this could produce, at most, the peak concentration of 70 pmol per 0.1 g liver *in vivo*. Actual PBPK sub-model simulations (not shown here) returned the highest sustained local concentrations in mouse of 65 pmol/0.1 g liver. However, since the PBPK sub-model was not validated with experimental data for liver concentrations *in vitro* vs. *in vivo*, these estimates remain tentative. Assuming that the free radical damage to a biological system is additive, the comparison of AUC for internal dose *in vivo* with the initial pro-oxidant concentration *in vitro* seems to be justified for the assessment of biological effects (such as lipid peroxidation).

Effects of Pro-Oxidant Chemicals on Lipid Peroxidation

From our *in vitro* experiments, presented in Figure 11, it appeared that lipid peroxidation is both time- and dose-dependent phenomenon; TBARS generation increased non-linearly with both increasing concentration of BrCCl_3 and increasing time of incubation. However, liver slices incubated with the highest BrCCl_3 concentration (1.5 mM) for 1 h generated slightly less TBARS than with the lower, 1 mM concentration of BrCCl_3 (Figure 11). This decrease is unlikely to be caused by the necrotic action of a high dose of BrCCl_3 acting for a prolonged time, since the liver slices were screened for signs of necrosis after the incubation. More probable is a mechanism of CYP suicide-inhibition caused by the accumulated damage to the enzyme by $\text{CCl}_3^\bullet$ and/or $\text{Br}^\bullet$ free radicals.

Similarly, BrCCl_3 administered *in vivo* showed non-linear time- and dose-dependent characteristics of lipid peroxidation stimulation, measured by ethane exhalation. This appeared from the data presented in Figures 12 and 13 that the maximum no-effect dose of BrCCl_3 of about 0.05 g/kg, when measured half an hour after the exposure, dropped to almost 0.025 g/kg after one hour from the exposure. On the other hand, the maximum stimulation of ethane exhalation, measured 1 h after the exposure, was reached at 0.1 g of BrCCl_3 /kg, while ten times as high a dose of BrCCl_3 was still not saturable when measured 0.5 h after the exposure (Figure 12). Even more dramatic differences were noted 2 h after the exposure (Figure 13); at 1g BrCCl_3 /kg, the ethane exhalation was still at the plateau level (0.33 p.p.m.), while ten times lower a dose (0.1 g BrCCl_3 /kg) caused twice as high stimulation of ethane exhalation (0.68 p.p.m.).

These results suggest that the extent of chemically induced oxidative stress and effects on lipid peroxidation are linked with both time and dose of BrCCl_3 by a non-linear function. The non-linearity may result from limited supply of antioxidants (threshold) and from accumulated over time free radical insult to the CYP enzymatic system (suicidal inhibition). Therefore,

considering biological effects and modeling *in silico* the dose-response for pro-oxidant chemicals, both independent variables (time and dose) were taken into account to assure realistic predictions and the same should be done in future risk characterizations.

Similar characterizations of the dose-response for TCE (Figures 10 and 16) led us to the estimate of an effective dose-response range of the local liver concentrations between 0.5 mM and 50 mM (or 0.05 to 5.0 $\mu\text{mol}/0.1\text{ g liver}$), and a maximum "no observable effect" dose of TCE *in vivo* (for up to 1 h) above 0.26 g/kg. These estimates suggested that TCE is about an order of magnitude less potent a pro-oxidant than BrCCl_3 (based on a mg of mass comparison). On the other hand, CCl_4 had a pro-oxidant potency similar to that of BrCCl_3 (Figures 14 and 17).

Parameters of lipid peroxidation and the feasibility of square root algorithm, which links concentration of pro-oxidant with production of free radicals, were determined in our experiments with mouse liver slices treated *in vitro* with TCE, CCl_4 , and BrCCl_3 . The calibrated algorithms and the parameters estimated *in vitro* were included in the PBPD model simulations of time- and dose-dependent effects of different doses of pro-oxidant chemicals on ethane exhalation in B6C3F1 mice *in vivo* (Figures 16 and 18 show examples of TCE and CCl_4 effects vs model predictions). It seems that the PBPD model described kinetics and dynamics of chemically induced lipid peroxidation relatively well, at least for TCE and CCl_4 .

EFFECTS OF FREE RADICALS ON CELLULAR TARGETS

Cellular effects of oxidative stress and free radical insult to cellular targets are well described in the literature (Byczkowski and Gessner, 1988; Kulkarni and Byczkowski, 1994a; 1994b; Byczkowski and Channel, 1996; Byczkowski and Kulkarni, 1996). Depending on the biochemical mechanism, the effects may include inhibition of enzymatic activities, inhibition of cellular transporter activities, uncoupling of oxidative phosphorylation and inhibition of the respiratory chain, interference with cellular membrane receptors and signal transduction pathway, deregulation of transcription and gene expression, and damage to vital macromolecules (lipids, proteins, and DNA). Cellular mechanisms and problems associated with risk characterization of pro-oxidant chemicals were reviewed in detail in the previous report by Byczkowski and Flemming (1995). Essentially, the interaction of pro-oxidant derived free radicals with cellular targets may be either specific (uniformly susceptible targets, suspended in the same phase as free radicals) or random (differently susceptible targets, or suspended in non-homogenous phases). The specific interactions were adequately described by deterministic module of our BBDR sub-

model (Figures 19 and 21), whereas random interactions were relatively well simulated by the stochastic module (Figures 20 and 21).

Setting a Hypothesis with the PBPD Model

There is growing body of evidence that pro-oxidant chemicals and oxidative stress can interfere with cellular signal transduction pathway (Byczkowski and Channel, 1996). Chen and Chan (1993) using 3T3-L1 cells, cultured in a serum-free medium, demonstrated that pro-oxidant chemicals (e.g., orthovanadate or DMNQ) increased [³H]thymidine incorporation to DNA and enhanced expression of the *c-fos* gene. The authors suggested that pro-oxidant compounds, causing oxidative stress, increased tyrosine protein phosphorylation early in the signal transduction cascade, leading to augmentation of cell proliferation (Chen et al., 1990; Chen and Chan, 1993). This effect may be accounted for by a selective effect on redox-sensitive protein tyrosine phosphatase (PTyrPase). Typically, PTyrPases contain a nucleophilic cysteinyl residue in their catalytic center (Stone and Dixon, 1994) and their enzymatic activities are rapidly inhibited by small disulfides (Ziegler, 1985). It seems that the cysteinyl residue must be kept in the reduced -SH form, therefore, thiol-directed reagents that oxidize it cause inhibition of PTyrPases (Fischer et al., 1991).

Accordingly, Mendelson et al., (1996) demonstrated that oxidative stress caused by CCl₄ in the liver, activated the *JNK* family of protein kinases and increased the AP-1 transcription factor binding to DNA. Because mitogen activated kinases (MAPK) must be kept phosphorylated to transmit this effect, it is possible, that inhibition of PTyrPase may stop deactivation of phosphatase MKP-1 which has high affinity for phosphorylated p38 as a substrate. This, in turn, may cause a rapid dephosphorylation of p38, which was down-regulated following the oxidative stress (Mendelson et al., 1996).

Since a similar subversion of signal transduction was suggested for TCE (Maronpot et al., 1995) but was never proved, it is possible that TCE-derived free radicals can affect intracellular redox potential and may lead to the inhibition of PTyrPase activity by causing oxidation of essential cysteinyl thiols. Our EPR spin trapping experiments confirmed the presence of free radicals in TCE-treated liver, but failed to reveal their identity (Steel-Goodwin et al., 1995; 1996). Assuming that the TCE-derived free radicals are well water-soluble (Gonthier and Barret, 1989; Mason, 1992; Ni et al., 1994), they should interact with PTyrPase suspended in the same phase as free radicals, in a specific way (the cysteinyl -SH residues represent uniformly susceptible targets). If this is the case, within the relevant TCE local concentrations in the liver, an

exponential inhibition of PTyrPase should be observed with a 50% inhibitory concentration around 0.5 mM (0.05 μmol TCE/0.1 g liver), as predicted by the BBDR sub-model. However, if only lipid-soluble secondary and tertiary, lipid peroxide-derived free radicals are available in the liver, they should result in a non-specific random inhibition of PTyrPase, giving a sigmoidal, dose-response with a 50% inhibitory concentration around 22.0 mM (2.2 μmol TCE/0.1 g liver; Figure 26).




Figure 26. The results of BBDR sub-model simulations of the expected inhibition of protein tyrosine phosphatase activity in the liver of mice *in vivo* after treatment with the estimated, effective pro-oxidant range of TCE doses (resulting in the local concentrations between $C_{\min} = 0.05$ and $C_{\max} = 5.0$ μmol TCE/0.1 g liver; other parameters are listed in Table 4).

TCE - local concentration of TCE in the liver [$\mu\text{mol}/0.1$ g liver]. A. INH - remaining percentage of uninhibited activity by the deterministic BBDR module ($\times 10^2$); I_{50A} - 50% inhibitory concentration (0.05 μmol TCE/0.1 g liver). B. PROB - remaining percentage of uninhibited activity by the stochastic BBDR module ($\times 10^2$); I_{50B} - 50% inhibitory concentration (2.2 μmol TCE/0.1 g liver).

Deterministic and stochastic PBPD model theoretical simulations (unconfirmed experimentally) of the remaining percentage of the enzymatic activity of protein tyrosine phosphorylase in the liver inhibited by TCE-derived free radicals specifically (Figure 26 A) and nonspecifically (Figure 26 B) showed quite different dose-dependent characteristics and different by two orders of magnitude I_{50} values, within the relevant range of TCE concentrations. Which dose-response profile will actually occur remains to be seen, but it was possible with the aim of the

PBPD model to simulate the predicted outcome within the relevant, internal pro-oxidant dosage of TCE, and set a verifiable working hypothesis for the future experimental research.

CONCLUSION

The resultant PBPD hybrid model may be used for pharmacodynamic description of chemically-induced oxidative stress in mice, for planning the future experiments and setting the verifiable working hypotheses, and potentially may be useful for a risk characterization.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the expert assistance of Maj (Dr.) S. Bachowski in parametrization of PBPK sub-model for CCl_4 with the data from literature, Maj (Dr.) L. Steel-Goodwin who performed the EPR spectroscopy analysis and TSgt R. Black, TSgt J. McCafferty, and Ms. C. Seckel who determined partition coefficients. This research was supported in part by the Department of the Air Force Environmental Initiative Program, AFOSR Work Unit 2312A202.

REFERENCES

- Antunes F., A. Salvador, H.S. Marinho, and R.E. Pinto. 1994. A mathematical model for lipid peroxidation in inner mitochondrial membrane. *Travaux de Laboratoire 33*[suppl. T-1]:1-52.
- Arterbery, V.E, W.A. Pryor, L. Jiang, S.S. Sehnert, W.M. Foster, R.A. Abrams, J.R. Williams, M.D. Wharam, Jr, and T.H. Risby. 1994. Breath ethane generation during clinical total body irradiation as a marker of oxygen-free-radical-mediated lipid peroxidation: a case study. *Free Radical Biol. Med.* 17:569-576.
- Babbs C.F. and M.G. Steiner. 1990. Simulation of free radical reactions in biology and medicine: a new two-compartment kinetic model of intracellular lipid peroxidation. *Free Radical Biol. Med.* 8:471-485.
- Biasi, F., M. Bosco, G. Lafranco, and G. Poli. 1995. Cytolysis does not per se induce lipid peroxidation: evidence in man. *Free Radical Biol. Med.* 18:909-912.
- Bray, T.M. and W.J. Bettger. 1990. The physiological role of zinc as an antioxidant. *Free Radical Biol. Med.* 8:281-291.
- Brendel, K.L., R.L. Fisher, C.L. Krumdieck, and A.J. Gandolfi. 1993. Precision-cut rat liver slices in dynamic organ culture for structure-toxicity studies. *Methods Toxicol.* 1A:222-226.
- Brendel, K.L., A.J. Gandolfi, C.L. Krumdieck, and P.F. Smith. 1987. Tissue slicing and culture revisited. *Trends Pharmacol. Sci.* 8:12-15.
- Buettner, G.R. 1987. Spin trapping: ESR parameters of spin adducts. *Free Radicals Biol. Medicine* 3: 259-303.
- Burdino, E., E. Gravela, G. Ugazio, V. Vannini, and A. Calligaro. 1973. Initiation of free radical reactions and hepatotoxicity in rats poisoned with carbon tetrachloride or bromotrichloromethane. *Agents Actions* 4:244-253.
- Burk, R.F. and J.M. Lane. 1979. Ethane production and liver necrosis in rats after administration of drugs and other chemicals. *Toxicol. Appl. Pharmacol.* 50:467-478.
- Byczkowski, J.Z. and S.R. Channel. 1996. Chemically-induced oxidative stress and tumorigenesis: effects on signal transduction and cell proliferation. *Toxic Subst. Mechan.* 15:101- 128.
- Byczkowski, J.Z., S.R. Channel, and T.L. Pravecsek. 1995. Development and experimental calibration of the mathematical model of lipid peroxidation in mouse liver slices. Tech. Report, AL/OE-TR-0179.
- Byczkowski, J.Z, S.R. Channel, T.L. Pravecsek, and C.R. Miller. 1996. Mathematical model for chemically induced lipid peroxidation in precision-cut liver slices: computer simulation and experimental calibration. *Comp. Meth. Progr. Biomed.* 50: 73-84.

Byczkowski, J.Z. and C.D. Flemming. 1995. Mathematical modeling of oxidative stress in vitro. Toxic Hazards Res. Unit Ann. Rep. No. AL/OE-TR-1996-0132.

Byczkowski, J.Z. and C.D. Flemming. 1996. Computer-aided dose-response characteristics of chemically initiated oxidative stress in vitro. 35th Annual Meeting of the Society of Toxicology, Anaheim, CA. Toxicologist 30: 240 (1227).

Byczkowski, J.Z., C.D. Flemming, C.R. Miller, W.J. Schmidt, and C.S. Seckel. 1996. Development and experimental calibration of biologically based dose-response model for oxidative stress. Society for Risk Analysis Annual Meeting, New Orleans, LA, Final Program, pp. 89, F1.03.

Byczkowski, J.Z. and T. Gessner. 1988. Biological role of superoxide ion-radical. Int. J. Biochem. 20: 569-580.

Byczkowski, J.Z. and A.P. Kulkarni. 1996. Pro-oxidant biological effects of inorganic components of petroleum: vanadium and oxidative stress. AL/OE-TR-1996-0126.

Channel, S.R., J.Z. Byczkowski, W.J. Schmidt, and C.R. Miller. 1997. Experimental verification of the mathematical model of trichloroethylene-induced lipid peroxidation in mouse liver slices. 36th SOT Annual Meeting, Cincinnati, OH. Toxicologist 36: 297 (1511).

Chen, Y. and T.M. Chan. 1993. Orthovanadate and 2,3-dimethoxy-1,4-naphthoquinone augment growth factor-induced cell proliferation and c-fos gene expression in 3T3-L1 cells. Arch. Biochem. Biophys. 305: 9-16.

Chen, Y.X., D.C. Yang, A.B. Brown, Y. Jeng, A. Tatoyan, and T.M. Chan. 1990. Activation of a membrane-associated phosphatidylinositol kinase through tyrosine-protein phosphorylation by naphthoquinones and orthovanadate. Arch. Biochem. Biophys. 238: 184-192.

Cojocel, C., W. Beuter, W. Muller, and D. Mayer. 1989. Lipid peroxidation: a possible mechanism of trichloroethylene-induced nephrotoxicity. Toxicology 55:131-141.

Comporti, M. 1985. Biology of disease, lipid peroxidation and cellular damage in toxic liver injury. Lab. Invest. 53:599-623.

Das, S.G., J.Z. Byczkowski, and J.W. Fisher. 1994. Probability analysis of TCE cancer bioassay data in the B6C3F1 mice using PBPK/PBPD modeling: a conceptual framework. Soc. for Risk Analysis Ann. Conf. and Expo., Final Program Abstracts, Baltimore, MD.

de Groot, H. and A. Littauer. 1989. Hypoxia, reactive oxygen, and cell injury. Free Radical Biol. Med. 6:541-551.

Evans, M.V. and M. Andersen. 1995. Sensitivity analysis and the design of gas uptake inhalation studies. Inhalation Toxicol. 7:1075-1094.

Evans, M.V., W.D. Crank, H.-M. Yang, and J.E. Simmons. 1994. Applications of sensitivity analysis to physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicol. Appl. Pharm. 128: 36-44.

Finley, J.W. and M.S. Otterburn. 1993. The consequences of free radicals in foods. *Toxicol. Ind. Health*. 9: 77-91.

Fischer, E.H., H. Charbonneau, and N.K. Tonks. 1991. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. *Science* 253:401-406.

Fisher, J.W., M.L. Gargas, B.C. Allen, and M.E. Andersen. 1991. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. *Toxicol. Appl. Pharmacol.* 109:183-195.

Gallo, J.M., L.L. Cheung, H.J. Kim, J.V. Bruckner, and W.R. Gillespie. 1993. A physiological and system analysis hybrid pharmacokinetic model to characterize carbon tetrachloride blood concentrations following administration in different oral vehicles. *J. Pharmacokinet. Biopharm.* 21:551-574.

Gardner, H.W. 1989. Oxygen radical chemistry of polyunsaturated fatty acids. *Free Radical Biol. Med.* 7:65-86.

Gargas, M.L. 1988. Tissue solubilities and biotransformation rates of halocarbons: experimental determinations and quantitative modeling. Ph.D. Dissertation, Wright State University, Dayton, OH.

Gargas, M.L., M.E. Andersen, and H.J. Clewell III. 1986. A physiologically based simulation approach for determining metabolic constants from gas uptake data. *Toxicol. Appl. Pharmacol.* 86:341-352.

Gargas, M.L., R.J. Burgess, D.E. Voisard, G.H. Cason, and M.E. Andersen. 1989. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. *Toxicol. Appl. Pharmacol.* 97:87-99.

Gonthier B.P. and L.G. Barret. 1989. In-vitro spin-trapping of free radicals produced during trichloroethylene and diethylether metabolism. *Toxicol. Lett.* 47:225-134.

Gower, J.D. 1988. A role for dietary lipids and antioxidants in the activation of carcinogens. *Free Radical Biol. Med.* 5: 95-111.

Guilbaud, R., A.C. Ricard, C. Daniel, S. Boileau, H.V. Tra, and G. Chevalier. 1994. A method to evaluate lipid peroxidation by automated analysis of exhaled pentane in human and rat breath. *Toxicology Methods* 4:1-11.

Haegle, A.D., S.P. Briggs, and H.J. Thompson. 1994. Antioxidant status and dietary lipid unsaturation modulate oxidative DNA damage. *Free Radical Biol. Med.* 16:111-115.

Hecht, D. and Y. Zick. 1992. Selective inhibition of protein tyrosine phosphatase activities by H_2O_2 and vanadate in vitro. *Biochem. Biophys. Res. Comm.* 188:773-779.

Heffetz, D., I. Bushkin, R. Dror, and Y. Zick. 1990. The insulinomimetic agents H_2O_2 and vanadate stimulate protein tyrosine phosphorylation in intact cells. *J. Biol. Chem.* 265: 2896-2902.

ILSI, RSI, International Life Sciences Institute, Risk Science Institute. 1994. Physiological Parameter Values for PBPK Models (Brown R, editor). A report prepared by ILSI, RSI under the cooperative agreement with the U.S. Environmental Protection Agency Office of Health and Environmental Assessment, Washington, DC.

Janero, D.R. 1990. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. *Free Radical Biol. Med.* 9:515-540.

Jeejeebhoy, K.N. 1991. In vivo breath alkane as an index of lipid peroxidation. *Free Radical Biol. Med.* 19:191-193.

Kappus, H. 1986. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. *Biochem. Pharmacol.* 35:1-6.

Kazui, M., K.A. Andreoni, E.J. Norris, A.S. Klein, J.F. Burdick, C. Beattie, S.S. Sehnert, W.R. Bell, G.B. Bulkley, and T.H. Risby. 1992. Breath ethane: a specific indicator of free-radical-mediated lipid peroxidation following reperfusion of the ischemic liver. *Free Radical Biol. Med.* 13:509-515.

Kedderis, G.L. 1996. Hepatic blood flow limitation of the bioactivation of hazardous chemical air pollutants. *Fund. Appl. Toxicol.* 30:34-35.

Kehrer, J.P. 1993. Free radicals as mediators of tissue injury and disease. *Crit. Rev. Toxicol.* 23: 21-48.

Kneepkens, C.M., G. Lepage, and C.C. Roy. 1994. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. *Free Radical Biol. Med.* 17:127-160.

Kohn, M.C., G.W. Lucier, G.C. Clark, C. Sewall, A.M. Tritscher, and C.J. Portier. 1993. A mechanistic model of effects of dioxin on gene expression in the rat liver. *Toxicol. Appl. Pharmacol.* 120:138-154.

Krumdieck, C.L., J.E. Dos Santos, and K.J. Ho. 1980. A new instrument for the rapid preparation of tissue slices. *Analyt. Biochem.* 104:118-123.

Kulkarni, A.P. and J.Z. Byczkowski. 1994a. Hepatotoxicity. In: *Introduction to Biochemical Toxicology* (Hodgson, E. and P.E. Levi, eds.), pp. 459 - 490, Appleton & Lange, Norwalk, CT.

Kulkarni, A.P. and J.Z. Byczkowski. 1994b. Effects of transition metals on biological oxidations. In: *Environmental Oxidants* (Nriagu, J.O., and M. Simmons, Eds.), pp. 475-496, John Wiley & Sons, Inc., New York, NY.

Larson J.L. and R.J. Bull. 1992. Metabolism and lipoperoxidative activity of trichloroacetate and dichloroacetate in rats and mice. *Toxicol. Appl. Pharmacol.* 115:268-277.

Maronpot, R.R., C.H. Anna, T.R. Devereux, G.W. Lucier, B.E. Butterworth, and M.W. Anderson. 1995. Considerations concerning the murine hepatocarcinogenicity of selected chlorinated hydrocarbons. *Prog. Clin. Biol. Res.* 391:305-323.

- Mason, R.P. 1992. Free radical metabolites of toxic chemicals and drugs as sources of oxidative stress. In: *Biological Consequences of Oxidative Stress* (Spatz, L., and A.D. Bloom, editors), pp. 23-49, Oxford University Press, New York, NY.
- McKenna R., F.J. Kezdy, and D.E. Epps. 1991. Kinetic analysis of the free-radical-induced lipid peroxidation in human erythrocyte membranes: evaluation of potential antioxidants using cis-parinaric acid to monitor peroxidation. *Anal. Biochem.* 196:443-450.
- Mendelson, K.G., L.R. Contois, S.G. Tevosian, R.J. Davis, and K.E. Paulson. 1996. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. *Proc. Natl. Acad. Sci. USA.* 93:12908-12913.
- Mitchell and Gauthier Associates, Inc. 1993. *Advanced Continuous Simulation Language (ACSL). Reference Manual.* Concord, MA.
- Ni Y.C., T.Y. Wong, F.F. Kadlubar, and P.P. Fu. 1994. Hepatic metabolism of chloral hydrate to free radical(s) and induction of lipid peroxidation. *Biochem. Biophys. Res. Comm.* 204:937-943
- Papas, A.M. 1993. Oil-soluble antioxidants in foods. *Toxicol. Ind. Health.* 9: 123-149.
- Paustenbach, D.J., G.P. Carlson, J.E. Christian, and G.S. Born. 1986. A comparative study of the pharmacokinetics of carbon tetrachloride in the rat following repeated inhalation exposures of 8 and 11.5 hr/day. *Fund. Appl. Toxicol.* 6:484-497.
- Paustenbach, D.J., H.J. Clewell III, M.L. Gargas, and M.E. Andersen. 1988. A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. *Toxicol. Appl. Pharmacol.* 96: 191 - 211.
- Poyer, J.L., R.A. Floyd, P.B. McCay, E.G. Janzen, and E.R. Davis. 1978. Spin trapping of the trichloromethyl radical produced during enzymatic NADPH oxidation in the presence of carbon tetrachloride and bromotrichloromethane. *Biochim. Biophys. Acta* 539:402-409.
- Pratt, D.E. 1993. Antioxidants indigenous to foods. *Toxicol. Ind. Health.* 9: 63-75.
- Refat, M., T.J. Moore, M. Kazui, T.H. Risby, J.A. Perman, and K.B. Schwartz. 1991. Utility of breath ethane as a noninvasive biomarker of vitamin E status in children. *Pediatr. Res.* 30:396-403.
- Riely, C.A., G.A. Cohen, and M. Lieberman. 1974. Ethane evolution: a new index of lipid peroxidation. *Science* 183:208-210.
- Roberfroid, M. and P.B. Calderon. 1994. *Free Radicals and Oxidation Phenomena in Biological Systems.* Marcel Dekker, Inc., New York, NY.
- Rosen, G.M. and E.J. Rauckman. 1982. Carbon tetrachloride-induced lipid peroxidation: a spin trapping study. *Toxicol. Lett.* 10:337-344.
- Sagai, M. and T. Ichinose. 1980. Age-related changes in lipid peroxidation as measured by ethane, ethylene, butane and pentane in respired gases of rats. *Life Sci.* 27:731-738.

- Sanzgiri, U.Y., H.J. Kim, S. Muralidhara, C.E. Dallas, and J.V. Bruckner. 1995. Effect of route and pattern of exposure on the pharmacokinetics and acute hepatotoxicity of carbon tetrachloride. *Toxicol. Appl. Pharmacol.* 134:148-154.
- Seckel, C.S. and J.Z. Byczkowski. 1996. Experimental parameters to support a pharmacodynamic model for ethane exhalation. 35th Annual Meeting of the Society of Toxicology, Anaheim, CA. *Toxicologist* 30: 244 (1247).
- Sipes, I.G., R.L. Fisher, P.F. Smith, E.R. Stine, A.J. Gandolfi, and K. Brendel. 1987. A dynamic liver culture system: a tool for studying chemical biotransformation and toxicity. *Arch. Toxicol. Suppl.* 11:20-33.
- Smith, C.V. 1991. Correlations and apparent contradictions in assessment of oxidant stress status in vivo. *Free Radical Biol. Med.* 10:217-224.
- Stadtman, E.R., C.N. Oliver, P.E. Starke-Reed, and S.G. Rhee. 1993. Age-related oxidation reaction in proteins. *Toxicol. Ind. Health.* 9: 187-196.
- Steel-Goodwin, L., T.L. Pravecsek, B.L. Hancock, W.J. Schmidt, S.R. Channel, D. Bartholomew, C.T. Bishop, M.M. Ketcha, and A.J. Carmichael. 1995. Trichloroethylene: free radical studies in B6C3F1 mouse liver slices. 34th Annual Meeting of the Society of Toxicology, Baltimore, MD, *Toxicologist* 15:30 (161).
- Steel-Goodwin, L., A.J. Carmichael, W.W. Schmidt, C. Miller, and J.Z. Byczkowski. 1996. Quantitation of free radicals in B6C3F1 mouse liver slices on exposure to four chemical carcinogens: an EPR/spin trapping study. 35-th Annual Meeting of the Society of Toxicology, Anaheim, CA. *Toxicologist* 30: 243 (1246).
- Steiner, E.C., T.D. Rey, and P.S. McCroskey. 1990. Simusolv Reference Guide. Modeling and simulation software. The Dow Chemical Company, Midland, MI.
- Stone, R.L. and J.E. Dixon. 1994. Protein-tyrosine phosphatases. *J. Biol. Chem.* 269: 31323-31326.
- Suzuki Y.J. and G.D. Ford. 1994. Mathematical model supporting the superoxide theory of oxygen toxicity. *Free Radical Biol. Med.* 16:63-72.
- Taffe, B.G., Takahashi, N., Kensler, T.W., and R.P. Mason. 1987. Generation of free radicals from organic hydroperoxide tumor promoters in isolated mouse keratinocytes. Formation of alkyl and alkoxyl radicals from tert-butyl hydroperoxide and cumene hydroperoxide. *J. Biol. Chem.* 262:12143-12149.
- Tappel, A.L., A.A. Tappel, and C.G. Fraga. 1989. Application of simulation modeling to lipid peroxidation process. *Free Radical Biol. Med.* 7:361-368.
- Timmins, G.S. and M.J. Davies. 1993. Free radical formation in isolated murine keratinocytes treated with organic peroxides and its modulation by antioxidants. *Carcinogenesis* 14:1615-1620.

Trush, M.A. and T.W. Kensler. 1991. An overview of the relationship between oxidative stress and chemical carcinogenesis. *Free Radical Biol. Med.* 10:201-209.

Videla, L.A., Barros S.B.M., and V.B.C. Junquiera. 1990. Lindane-induced liver oxidative stress. *Free Radical Biol. Med.* 9:169-179.

Vroegop, S.M., D.E. Decker, and S.E. Buxser. 1995. Localization of damage induced by reactive oxygen species in cultured cells. *Free Radical Biology and Medicine* 18:141-151.

Williams, G.M. 1993. Inhibition of chemical-induced experimental cancer by synthetic phenolic antioxidants. *Toxicol. Ind. Health.* 9: 303-308.

Willis, R.J. 1980. Possible role of endogenous toxigenic lipids in the carbon tetrachloride poisoned hepatocyte. *Federation Proc.* 39:3134-3137.

Yang, S.H. and M.E. Andersen. 1994. Pharmacokinetics. In: *Introduction to Biochemical Toxicology* (Hodgson, E. and P.E. Levi, eds.), pp. 49 -73, Appleton & Lange, Norwalk, CT.

Ziegler, D.M. 1985. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. *Ann. Rev. Biochem.* 54: 305-329.

APPENDIX: Source Codes of PBPD Model Written in ACSL®

• PBPD Sub-Model

Sub-Model for Pro-Oxidant Induced Lipid Peroxidation *.CSL FILE

'This PBPD sub-model predicts ethane exhalation by mice in a closed '
'chamber after dosing with CCl4, TCE and BrCCl3 based on TBARS'
'model published by Byczkowski et al., 1996; interlinked with '
'PBPK/TCPK sub-model Das et al., 1994 and Seckel and Byczkowski'
'1996. Final version 1/03/97'

PROGRAM: PBPD FOR P-OX-INDUCED OXIDATIVE STRESS

INITIAL

```
LOGICAL    CC          '$Flag set to .TRUE. for closed chamber runs'

'      Miscellaneous commands
CONSTANT   CC = .true.   '$Default to close chamber
CONSTANT   PBPK = 1.     '$Default to interlink with PBPK model
'                                     to use two-compartment CPK switch PBPK=0.
CONSTANT   CPK= 0.       '$Switch CPK=1 to use two-compartment PK

'PEROXIDATION PARAMETERS FOR LIVER [per 0.1 g of liver]

CONSTANT   PUF   = 7.0      '$[micromol/0.1 g liver]
CONSTANT   PXZLUF= 12.0     '$peroxidizability of PUFA L[1/h]
CONSTANT   PXZHUF= 24.0     '$peroxidizability of PUFA H[1/h]
CONSTANT   ANOX1 = 0.0037   '$Vit.E antiox[mcmol/0.1g liv]
CONSTANT   ACT1  = 0.0003   '$activator1[mcmol cytP450/0.1gliv]
CONSTANT   GSH   = 0.6      '$glutathione [mcmol/0.1 g liver]
CONSTANT   PXTTBA= 0.1      '$yield of TBARS/mol hydroperoxide
CONSTANT   LPUF  = 3.        '$LA-derivative PUFA[mcmol/0.1 g]
CONSTANT   HPUF  = 4.        '$HA-derivative PUFA[mcmol/0.1 g]
CONSTANT   ANOX2 = 0.        '$non-Vit.E antiox[mcmol/0.1 g liv]
CONSTANT   ANOX3 = 0.        '$added antioxidant[mcmol/0.1g liv]
CONSTANT   EFANO1= 1.        '$effectiveness of Vit.E
CONSTANT   EFANO2= 0.        '$effectiveness of non-Vit.E a-o
CONSTANT   EFANO3= 0.        '$effectiveness of added a-o
CONSTANT   ANOXUF= 2.        '$antioxidant use factor [1/mcmol]
CONSTANT   ACT2  = 0.        '$activator 2 [mcmol/0.1 g liver]
CONSTANT   AACT1 = 1.        '$activity of activator 1
CONSTANT   AACT2 = 0.        '$activity of activator 2
CONSTANT   ACTDGF= 1.75     '$activator degradation fctr [1/mcmol]
CONSTANT   IND2  = 0.        '$inducer2[mcM chemical/0.1g liv]
CONSTANT   PTIND1= 4408.    '$potency of inducer 1 [1/mcmol]
CONSTANT   PTIND2= 0.        '$potency of inducer 2 [1/mcmol]
CONSTANT   INDLF = 0.0001   '$inducer loss factor [1/h]
CONSTANT   PXRATE= 0.00029  '$peroxidation rate [mcmol/mcmol]
CONSTANT   AUTOXF= 0.00013  '$autooxidation factor [1/h]
CONSTANT   GPENZA= 1.        '$glutathione peroxidase[1/mcmol]
CONSTANT   PXREDF= 0.17     '$hydroperoxide reduction factor [1/h]
CONSTANT   PHYSPX= 0.        '$physiological levels of Hperoxides
CONSTANT   ANREG  = 0.0007   '$antioxidant regenerated in situ
CONSTANT   ANOXR  = 0.001    '$antioxidant regeneration rate constant
CONSTANT   BCKGD  = 0.0      '$TBARS in control [mcm/0.1 g]
CONSTANT   ACR    = 0.025    '$activator degradation rate constant
```

'TIMING COMMANDS

```

CONSTANT      POINTS = 200.
CINT=TSTOP/POINTS
CONSTANT  TCHNG = 4.0   '$Length of inhalation exposure to P-Ox [h]
CONSTANT   TINF = 0.01  '$Length of IV infusion with P-Ox [h]

'repeated gavage dosing
constant   DAYS=0.08333 '$Duration of simulation [DAYS] if pdays=0.
constant   pdays=0.    '$No-gavage days in cycle

'PARAMETERS FOR MOUSE IN VIVO

CONSTANT   KLC = .050   '$First order chamber loss [Lin fraction/h]
CONSTANT   KS = 100000. '$Suppression rate constant for metabolism
CONSTANT   AVBW = 38.0  '$Average BW of mice=Tot W/n [g]
          BW = AVBW/1000    '$Average body weight per mouse [kg]

CONSTANT   QPC = 30.00  '$Alveolar ventilation rate [l/h]
CONSTANT   QCC = 16.5   '$Cardiac output [l/h]
          QLC = 0.24 - QGC
CONSTANT   QGC = .175   '$Fractional blood flow to gut
CONSTANT   QFC = .05    '$Fractional blood flow to fat
CONSTANT   QSC = .238   '$Fractional blood flow to slow
CONSTANT   QRC = .472   '$Fractional blood flow to rapid

CONSTANT   VLC = .05    '$Fraction liver tissue
CONSTANT   VGC = .033   '$Fraction gut tissue
CONSTANT   VSC = .558   '$Fraction slow tissue
CONSTANT   VRC = .031   '$Fraction rapid tissue
CONSTANT   VFC = .1     '$Fraction fat tissue

'      PARAMETERS FOR ETHANE
CONSTANT   PLA = 0.828  '$Liver/air partition coefficient
CONSTANT   PGA = 0.996  '$Gut/air partition coefficient
CONSTANT   PFA = 2.444  '$Fat/air partition coefficient
CONSTANT   PSA = 0.979  '$Slowly perfused tissue/air partition
CONSTANT   PRA = 0.996  '$Richly perfused tissue/air partition
CONSTANT   PEB = 1.305  '$Blood/air partition coefficient

PEL=PLA/PEB  '$Liver/blood partition coefficient
PEG=PGA/PEB  '$Gut/blood partition coefficient
PEF=PFA/PEB  '$Fat/blood partition coefficient
PES=PSA/PEB  '$Slow/blood partition coefficient
PER=PRA/PEB  '$Rich/blood partition coefficient

CONSTANT   BACKE=0.     '$Background ethane concentration [ppm]
CONSTANT   MEW = 30.    '$Molecular weight Et [g/mol]

CONSTANT   VMEXC=0.286  '$Maximum velocity of metabolism [mg/h-1kg]
CONSTANT   KEM = 0.51   '$Michaelis-Menten constant [mg/L]
CONSTANT   KEFC= 2.786  '$First order metabolism rate constant[l/h-1kg]
CONSTANT   NRATS= 5.    '$Number of mice [for closed chamber]
CONSTANT   VCHC = 0.745 '$Volume of closed chamber [L]
CONSTANT   SODA =0.005  '$Volume of soda lime [L]

'      PARAMETERS FOR P-Ox
CONSTANT   BAB = 0.99   '$Fraction absorbed from i.p. to portal blood
CONSTANT   FAB = 0.0001 '$Fraction absorbed from i.p. directly to fat
          Note: (BAB + FAB) < 1.

'Carbon Tetrachloride - specific constants
CONSTANT   PLCC = 3.14  '$Liver/blood partition coefficient

```

```

CONSTANT PFCC = 79.4 $'Fat/blood partition coefficient
CONSTANT PRCC = 3.14 $'Richly perfused tissue/blood partition
CONSTANT PBCC = 4.52 $'Blood/air partition coefficient
CONSTANT PSCC = 2.43 $'Slowly perfused tissue/blood partition

CONSTANT MWCC =153.82 $'Molecular weight P-Ox [g/mol]
CONSTANT DOSE = 0. $'Dose of active P-Ox [mg/kg]
'Estimate of initial concentration of chemical in the liver [mg/L]
  CLO = DOSEIP/VLC
CONSTANT KAIP = 1.45 $'First order i.p. uptake [1/h]
CONSTANT DOSEIP = 1500. $'i.p. dose [mg/kg]
  DIP = DOSEIP*BW $'i.p. dose per animal [mg]
CONSTANT PDOSEC = 0. $'Oral dose [mg/kg]
  DOSEC = PDOSEC*BW $'p.o. dose per animal [mg]
CONSTANT KAC = 1. $'Oral uptake rate [1/hr]

CONSTANT IVDOSC = 0. $'i.v. dose [mg/kg]

CONSTANT CONCC =0. $'Inhaled concentration [ppm]

'Metabolic constants for CCl4 '
CONSTANT VMAXCC=0.65 $'Maximum velocity of metabolism [mg/h-1kg]
CONSTANT KMC = 0.25 $'Michaelis-Menten constant CCl4 [mg/L]
CONSTANT KFCC= 0.0 $'First order metabolism rate constant [1/h-1kg]

'Pharmacokinetic transfer constants fitted
CONSTANT k10 = 0.3 $'Pharmacokinetic transfer micro-constant [1/h]
CONSTANT alpha= 1.5 $'Pharmacokinetic macro-constant [1/h]
CONSTANT beta= 1.6 $'Pharmacokinetic macro-constant [1/h]

CONSTANT EFCE =0.001 $'Efficiency of ethane generation [molar ratio]

' Inhalation P-Ox Exposure definition
IF (CC) RATS = NRATS $'Closed chamber simulation
IF (CC) KL = KLC

IF (.NOT.CC) RATS = 0. $'Open chamber simulation
IF (.NOT.CC) KL = 0.
'Turn off chamber losses so concentration remains constant

AI0C = CONCC*VCH*MWCC/24450. $'Initial amount of P-Ox in chamber [mg]

' PARAMETERS FOR CLOSED CHAMBER
CONE= BACKE
VCH = VCHC-(RATS*BW)-SODA $'Net chamber volume [L]
AEI0 = CONE*VCH*MEW/24450. $'Initial amount of E in chamber [mg]

' INITIALIZATION
'RESETS INITIAL CONDITIONS BEFORE PEROXIDATION
CONSTANT ACTLOS=0. $'activator loss
CONSTANT AUTOX =0. $'autooxidation
CONSTANT PXREDG=0. $'Hydroperoxides red. by GSH peroxidase'
CONSTANT PXLUF =0.00199 $'L-Hydroperoxides formed
CONSTANT PXHUF =0.0053 $'H-Hydroperoxides formed
CONSTANT PXREM =0. $'accumulated remaining Hydroperoxides '
CONSTANT TPX =0. $'accumulated total Hydroperoxides formed'
CONSTANT ILR =0. $'rate of inducer loss = 0.
CONSTANT CL = 0. $'no inducer
'Reset output arrays at initialization
ETH = 0.
CONC= 0.

```

```

'      Scaled parameters for mouse
      QC = QCC*BW**0.74
      QP = QPC*BW**0.74
      QL = QLC*QC
      QG = QGC*QC
      QF = QFC*QC
      QS = 0.24*QC-QF
      QR = 0.76*QC-QL-QG
      QLB= QL+QG
      VL = VLC*BW
      VG = VGC*BW
      VF = VFC*BW
      VS = 0.82*BW-VF
      VR = 0.101*BW-VL-VG
      VMEX = VMEXC*BW**0.7
      KEF = KEFC/BW**0.3
      VEK = VMEXC/KEM
      VMAXC4 = VMAXCC*BW**0.7
      KFC4 = KFCC/BW**0.3

INTEGER DAY

'      Repeated gavage dosing with P-Ox
      tstop= (days+PDAYS)*24.
      CINT= tstop/points
      DAY=-1.  $'TO START GAVAGE ON MONDAY -1, TUES 0, WEDN 1, ETC

END                                     $'End of Initial

DYNAMIC

'      GAV = FEED MICE p.o. with P-Ox YES=1, NO=0.
DISCRETE CAT1
      INTERVAL CAT = 24.          $'EXECUTE CAT1 EVERY 24 hr
      DAY=DAY+1
      IF(DAY.GT.DAYS) GOTO OUT
      IF(MOD(DAY,7).GE.5) GOTO OUT
      GAV = 1.                    $'GAVAGE = YES
      SCHEDULE CAT2 .AT. T+0.01  $'SCHEDULE END OF GAVAGE
      OUT.. CONTINUE
END      $'END OF CAT1

DISCRETE CAT2
      GAV = 0.                    $'GAVAGE = NO
END      $'END OF CAT2

ALGORITHM IALG = 2                  $'Gear stiff method
DERIVATIVE
'-----
'      <<<<MODULE LOCAL DOSE OF P-Ox>>>>
'
'Estimate of actual conc. of chemical in the liver CL(C) [mg/L] by two-
'compartment open-system classic pharmacodynamic CPK sub-model as CL.
'Alternatively, CL(C) is calculated continuously by PBPK sub-model as
'CLC'
'-----
'      <<<<SUB-MODEL CPK>>>>

CL = CL0*k10*(exp(-beta*t)-exp(-alpha*t))/(alpha - beta)

```

```

'-----'
'          <<<<SUB-MODEL PBPK FOR P-Ox>>>>
'
'Includes code for suppression of metabolism
IVRC = IVDOSC*BW/TINF
'
'    i.p. dosing with P-Ox
RMRIP = -KAIP*MRIP $'Rate of change of amount in i.p. cavity [mg/h]
MRIP = INTEG(RMRIP,DIP) $'Amount of toxicant in i.p. cavity [mg]
'
'    AIP = amount of P-Ox absorbed from i.p.
RAIP = KAIP*MRIP $'Rate absorption from i.p. cavity [mg/h]
AIP = DIP - MRIP $'Amount of toxicant absorbed from i.p. [mg]
'
'    CIC = Concentration in inhaled air [mg/L]
CIZONE = RSW((T.LT.TCHNG).OR.CC,1.,0.)
RAIC = RATS*QP*(CAC/PBCC-CIC) - (KLC*AIC)
AIC = INTEG(RAIC,AI0C)
CIC = AIC/VCH*CIZONE
CP = CIC*24450./MWCC
'
'    Repeated gavage dosing with P-Ox
'
'    MRC = Amount remaining in stomach [mg]
RMRC = gav*dosec/tinf - raoc
MRC = integ(rmrc,0.)
'
'    AOC = total mass input from stomach
RAOC = kac*mrc
AOC = integ(raoc,0.)
'
'    AGC = Amount in gut [mg]
RAGC = QG*(CAC-CVGC) $'This is in addition to RAOC
AGC = INTEG(RAGC,0.)
CVGC = AGC/(VG*PRCC)
CGC = AGC/VG
'
'    CAC = Concentration in arterial blood [mg/L]
CAC = (QC*CVC+QP*CIC)/(QC+(QP/PBCC))
AUCBC = INTEG(CAC,0.)
'
'    AXC = Amount exhaled [mg]
CXC = CAC/PBCC
CXPPMC = (0.7*CXC+0.3*CIC)*24450./MWCC
RAXC = QP*CXC
AXC = INTEG(RAXC,0.)
'
'    ASC = Amount in slowly perfused tissues [mg]
RASC = QS*(CAC-CVSC)
ASC = INTEG(RASC,0.)
CVSC = ASC/(VS*PSCC)
CSC = ASC/VS
'
'    ARC = Amount in rapidly perfused tissues [mg]
RARC = QR*(CAC-CVRC)
ARC = INTEG(RARC,0.)
CVRC = ARC/(VR*PRCC)
CRC = ARC/VR
'
'    AFC = Amount in fat tissue [mg]

```



```

END      '$End of procedural
'
'*****BBPB SUB-MODEL FOR LIPID PEROXIDATION*****'
'-----'
' #s Corresponding to equations in Byczkowski et al. (1996)
' This part has been calibrated in vitro in mouse liver slices
'-----'
'1. Remaining polyunsaturated fatty acids [micromol/0.1gliv]
'
LPUFRE = LPUF - PXLUFA - AUTOXA/2
HPUFRE = HPUF - PXHUFA - AUTOXA/2
'2. Effective activator [micromoe/0.1 g liver]
'
ACTEF = ACT1*ACACT1 + ACT2*ACACT2
'3. Activator loss [micromole/0.1 g liver]
'
ACTLOS = ACTEF*ACTDGF*TPX
'4. Remaining activator [micromole/0.1 g liver]
'
ACTREM = (ACTEF - ACTLOS)*exp(-ACR*INDREM*t)
'5. Effective inducer [micromole/0.1 g liver]
'
INDEF = SQRT(IND1*PTIND1) + IND2*PTIND2
'6. Remaining inducer [micromole/0.1g liv]
'
INDREM = INDEF - INDLOS
'6.a. Inducer loss rate [micromol/0.1 g liver/hr]
'
ILR = INDEF*INDLF
'7. Activated inducer [micromol/0.1 g liver]
'
ACTIND = INDREM*ACTREM
'8. Effective antioxidant [micromol/0.1g liver]
'
ANOXEF = ANOX1*EFANO1 + ANOX2*EFANO2 + ANOX3*EFANO3
'9. Remaining antioxidant [mcromol/0.1 g]
'
ANOXRE = ANOXEF - ANOXEF*TPX*ANOXUF + ANREG*exp(-ANOXR*t)
'10. Hydroperoxides formed by action of activated inducer on
' PUFA [micromol/0.1 g liver/hr]
'
PXLUF = LPUFRE*PXZLUF*ACTIND*PXRATE/ANOXRE
PXHUF = HPUFRE*PXZHUF*ACTIND*PXRATE/ANOXRE
'12. Autooxidation [micromole/0.1 g liver/hr]
'
AUTOX = (LPUFRE + HPUFRE)*AUTOXF*TPX/ANOXRE
'14. Accumulated total hydroperoxides formed [mcmol/0.1 g liver]'

```

```

TPX = AUTOXA + PXLUFA + PXHUFA + PHYSPX

'15.Remaining glutathione [micromol/0.1 g liver]
GSHREM = GSH - PXREDA

'16.Hydroperoxides reduced by glutathione peroxidase
' [micromol/0.1 g liver/hr]
PXREDG = PXREM*GPENZA*GSHREM*PXREDF

'18.Accumulated remaining hydroperoxides [micromole/0.1 g liv.]
PXREM = TPX - PXREDA

'19.Amount of TBARS from accumulated remaining hydroperoxides
' [micromol/0.1 g liver]
TBARS = PXREM*PXTTBA + BCKGD

' Inducer lost over time [micromol/0.1 g liver]
INDLOS = INTEG(ILR,0.)

'11.Accumulated hydroperoxides formed by action of activated
' inducer on PUFA [micromole/0.1 g liver]
PXLUFA = INTEG(PXLUF, 0.)
PXHUFA = INTEG(PXHUF, 0.)

'13.Accumulated autooxidation [micromol/0.1 g liver]
AUTOXA = INTEG(AUTOX, 0.)

'17.Accumulated hydroperoxides reduced by glutathione
' [micromole/0.1 g liver]
PXREDA = INTEG(PXREDG, 0.)
'-----
'^^^^^End of BBPD Sub-model for lipid peroxidation^^^^^^^^^^^^^^^^^^^^
'-----
'-----LINK-----
'Link with Accumulated Remaining Hydroperoxides produced in the liver
'Assumed lipid peroxidation in the liver only, evoked by P-Ox
concentration'
'Lipid peroxidation is driven by hydroperoxides generated by free
'radicals depending on SQRT of local concentration of P-Ox in liver

ETH = PXREM*EFFE $'Molar Amount of ethane produced [mCM/0.1 g liver]
'Rate of evolution of ethane produced in the liver [mg E/hr/mouse]
REOX=(ETH*VL*300)/(t+1e-12)
'REOX = f(SQRT(RPOX))
'300=MEW/1000/0.0001 over time prevented to start from dividing by 0
'-----
'<<<<MODULE ETHANE EXHALATION>>>>

```

```

'This part has been calibrated in mice in vivo
'
'*****PBPB SUB-MODEL FOR ETHANE*****'
'
'   CEI = Concentration in inhaled air (mg/L)
'   REAI = RATS*QP*(CEA/PEB-CEI)-(KL*AEI)
'   AEI = INTEG(REAI,AEI0)
'   CEI = AEI/VCH
'   CEP = CEI*24450./MEW
'           $ 'Chamber
'           $ 'With N mice
'           $ 'concentration in closed chamber
'
'-----'
'
'   CEA = Concentration in arterial blood [mg/L]
'   CEA = (QC*CEV+QP*CEI)/(QC+(QP/PEB))
'
'   AEX = Amount exhaled per mouse [mg]
'   CEX = CEA/PEB
'   CXEPM = (0.7*CEX+0.3*CEI)*24450./MEW
'   REAX = QP*CEX
'   AEX = INTEG(REAX,0.)
'
'   AES = Amount in slowly perfused tissues per mouse [mg]
'   REAS = QS*(CEA-CEVS)
'   AES = INTEG(REAS,0.)
'   CEVS = AES/(VS*PES)
'   CES = AES/VS
'
'   AER = Amount in rapidly perfused tissues per mouse [mg]
'   REAR = QR*(CEA-CEVR)
'   AER = INTEG(REAR,0.)
'   CEVR = AER/(VR*PER)
'   CER = AER/VR
'
'   AEF = Amount in fat tissue per mouse [mg]
'   REAF = QF*(CEA-CEVF)
'   AEF = INTEG(REAF,0.)
'   CEVF = AEF/(VF*PEF)
'   CEF = AEF/VF
'
'   AEG = Amount in gut tissue per mouse [mg]
'   REAG = QG*(CEA-CEVG)
'   AEG = INTEG(REAG,0.)
'   CEVG = AEG/(VG*PEG)
'   CEG = AEG/VG
'
'   AEL = Amount in liver tissue per mouse [mg]
'   REAL = QL*(CEA-CEVL)+QG*(CEVG-CEVL)-REAM+REOX
'   AEL = INTEG(REAL,0.)
'   CEVL = AEL/(VL*PEL)
'   CEL = AEL/VL
'
'   AEM = Amount metabolized per mouse w/suppression (KS) [mg]
'   REAM = (VMEX*CEVL)/(KEM+CEVL*(1+CEVL/KS)) + KEF*CEVL*VL $ '[mg/h]
'
'   AEM = INTEG(REAM,0.)
'           $ 'Amount [mg]
'
'   CEV = Mixed venous blood concentration per mouse [mg/L]
'   CEV = (QF*CEVF+ (QL+QG)*CEVL+ QS*CEVS+ QR*CEVR)/QC
'
'AMOUNT INHALED PER MOUSE
'   REINH = QP*CEI
'   AEINH = INTEG(REINH,0)

```


0.08300	0.988875
0.17000	0.966695
0.25000	0.961003
0.33000	0.903836
0.50000	0.822943
0.75000	0.743472
1.00000	0.946910
1.25000	0.599756
1.50000	0.564610
1.75000	0.530173
2.00000	0.387864
2.25000	0.443700
2.50000	0.384679
2.75000	0.348181
3.00000	0.311571

END \$'END OF DATA'

START

PLOT CEP

END

PROCED CONDCCL

'TABLE 1&2: CHEMICAL-SPECIFIC CONDITIONS FOR LIPID PEROXIDATION BY CCl4'

SET PTIND1=4408., ACR=0.025,

SET k10=0.3, alpha=1.5, beta=1.6, KAIP=1.45

SET ACTDGF=1.75, INDLF=0.0001, MWCC=153.8

SET ANREG=0.0007, ANOXR=0.001

END

PROCED FIG17A

'Ethane Exhalation after CCl4 0.075 g/kg'

SET TITLE = 'ETHANE EXHALATION AFTER CCl4'

PREPAR t, 'ALL', CL

SET DAYS=0.083333, NRWITG=.F.

SET BACKE=0., POINTS=300, AVBW=32.82

SET DOSEIP=75.

'[h] [ppm]'

DATA

T CEP

0. 0.

0.0833 0.027758

0.166667 0.081802

0.25 0.057029

0.333333 0.030957

0.416667 0.019462

0.5 0.04063

0.75 0.046445

1. 0.035008

1.25 0.097736

1.5 0.120978

1.75 0.121889

2. 0.184791

END \$'END OF DATA'

START

PLOT CEP, 'lo'=0., 'hi'=0.25, 'xhi'=2.2

END \$'End of file'

PROCED FIG17B

'Ethane Exhalation after CCl4 0.15 g/kg'

```

SET TITLE = 'ETHANE EXHALATION AFTER CCl4'
PREPAR t, 'ALL', CL
SET DAYS=0.083333, NRWITG=.F.,
SET BACKE=0., POINTS=200, AVBW=32.56
SET DOSEIP=150.

```

```

'[h]          [ppm]'
DATA
T              CEP
0.             0.
0.0833         0.
0.166667      0.
0.25           0.010312
0.333333      0.043063
0.416667      0.071015
0.5            0.020494
0.75           0.107916
1.             0.089671
1.25           0.076225
1.5            0.099269
1.75           0.076916
2.             0.042414
END $'END OF DATA'
START

```

```

PLOT CEP, 'lo'=0., 'hi'=0.25, 'xhi'=2.2
END          $'End of file'

```

```

PROCED FIG17C
'Ethane Exhalation after CCl4 0.3 g/kg'
SET TITLE = 'ETHANE EXHALATION AFTER CCl4'
PREPAR t, 'ALL', CL
SET DAYS=0.083333, NRWITG=.F.,
SET BACKE=0., POINTS=200, AVBW=38.
SET DOSEIP=300.

```

```

'[h]          [ppm]'
DATA
T              CEP
0.             0.
0.0833         0.
0.166667      0.038776
0.25           0.072132
0.333333      0.070974
0.416667      0.123789
0.5            0.096211
0.75           0.109947
1.             0.097474
1.25           0.092724
1.5            0.073632
1.75           0.110104
2.             0.095158
END $'END OF DATA'
START

```

```

PLOT CEP, 'lo'=0., 'hi'=0.25, 'xhi'=2.2
END          $'End of file'

```

```

PROCED FIG17D
'Ethane Exhalation after CCl4 1.5 g/kg'
SET TITLE = 'ETHANE EXHALATION AFTER CCl4'

```

```

PREPAR t, 'ALL', CL
SET DAYS=0.083333, NRWITG=.F.,
SET BACKE=0., POINTS=300, AVBW=31.8
SET DOSEIP=1500.

```

```

'[h]          [ppm]'
DATA
T             CEP
0.            0.
0.0833       0.
0.166667     0.
0.25         0.065464
0.333333     0.090988
0.416667     0.027442
0.5          0.059182
0.75         0.170162
1.           0.194608
1.25         0.148473
1.5          0.175496
1.75         0.132515
2.           0.182836
END $'END OF DATA'
START

```

```

PLOT CEP, 'lo'=0., 'hi'=0.25, 'xhi'=2.2
END          $'End of file'

```

```

PROCED FIG18
'Ethane Exhalation after CCl4 1.5, 0.3, 0.15, 0.075 g/kg'
SET TITLE = 'ETHANE EXHALATION AFTER CCl4'
PREPAR /clear t, CEP
SET DAYS=0.083333, NRWITG=.T., FTSPLT=.T.
SET BACKE=0., POINTS=300.
SET AVBW=35.
SET NRATS=5,
SET DOSEIP=75.
START

```

```

SET DOSEIP=150.
START

```

```

SET DOSEIP=300.
START

```

```

SET DOSEIP=1500.

```

```

'[h]          [ppm]'
DATA
T             CEP             INITIAL
0.            0.
0.0833       0.
0.166667     0.
0.25         0.065464
0.333333     0.090988
0.416667     0.027442
0.5          0.059182
0.75         0.170162
1.           0.194608
1.25         0.148473
1.5          0.175496
1.75         0.132515

```

```

2.      0.182836
0.      0.      INITIAL
0.0833  0.
0.166667 0.038776
0.25     0.072132
0.333333 0.070974
0.416667 0.123789
0.5      0.096211
0.75     0.109947
1.       0.097474
1.25     0.092724
1.5      0.073632
1.75     0.110104
2.       0.095158
0.      0.      INITIAL
0.0833  0.
0.166667 0.
0.25     0.010312
0.333333 0.043063
0.416667 0.071015
0.5      0.020494
0.75     0.107916
1.       0.089671
1.25     0.076225
1.5      0.099269
1.75     0.076916
2.       0.042414
0.      0.      INITIAL
0.0833  0.027758
0.166667 0.081802
0.25     0.057029
0.333333 0.030957
0.416667 0.019462
0.5      0.04063
0.75     0.046445
1.       0.035008
1.25     0.097736
1.5      0.120978
1.75     0.121889
2.       0.184791
END $'END OF DATA'
START

```

```

PLOT CEP, 'lo'=0., 'hi'=0.25, 'xhi'=2.2
END      $'End of file'

```

PBPD Sub-Model *.CMD FILE for TCE

```

PROCED FIG16
SET TITLE='MICE ETHANE AFTER TCE:2.6,1,0.26g/kg'
SET TSTOP=2., NRWITG=.t.,
PREPAR t, 'all'
SET k10=0.03, alpha=0.01, beta=2.0, EFFE=0.001,
SET PBCC=13.4, PLCC=2.03, PFCC=41.3, PRCC=2.03, PSCC=1.
SET MWCC=131.5, VMAXCC=33., KMC=0.25, KFCC=2.4
SET ACTDGF=0.0014, PTIND1=250, KAIP=1., DOSE=2600.,
START

```

```
SET DOSE=1000.
START
```

```
SET DOSE=260.
```

```
'[h]    [ppm] '
DATA
T        CEP
0.        0.000001    INITIAL
0.25     0.036148
0.333    0.027971
0.75     0.038132
1.        0.042805
1.25     0.045230
1.5      0.093413
1.75     0.075427
2.        0.110495
0.        0.000001    INITIAL
0.1667   0.032907
0.25     0.016053
0.3333   0.026683
1.5      0.026005
1.75     0.056478
2.        0.060730
0.        0.000001    INITIAL
0.75     0.034561
```

```
END      '$end of data'
START
```

```
PLOT CEP, CLC, 'xhi'=2.
```

```
END      '$end of file'
```

```
*****
```

• BBDR Sub-Model

Deterministic and stochastic modules *.CSL FILE

```
PROGRAM: FREE RADICAL DOSE RESPONSE
```

```
'A program that calculates amount of free radicals from initial '
'local concentration of P-Ox and estimates their cellular effect '
'based on Vroegop et al. 1995. Final version for SIMUSOLV 1/10/97'
```

```
==      OPEN(UNIT=41,STATUS='NEW',FILE='GRAPHG.FIG')
```

```
WRITE(41,10)
```

```
10..FORMAT(' PROC NDATA'/ ' DATA'/ ' PCONC          PROB')
```

```
INITIAL          '$Pre-execution section of program'
```

```
CONSTANT ki =0.001 '$rate constant of free radical formation'
```

```
CONSTANT kt =0.002 '$rate constant of free radical recombination'
```

```
'      ki      kt
```

```
'C ---> FR + FR ---> Nonradical products'
```

```
'assuming early phase C=C0, and the steady state condition:'
```

```
'dFR/dt = ki*C0 - kt*FR*FR = 0. (const. ki, kt [1/uM*h])'
```

```
CONSTANT kd = 0.075 '$rate constant of receptor inactivation'
```

```
'      kd
```

```
'FR + RECEPTOR ---> RECEPTOR Inactive'
```

```
'assuming first order process for receptor inactivation and'
```

```
'uniform sensitivity fo FR with rate constant kd [100%/uM*h]'
```

```
CONSTANT IO = 1.    '$Initial concentration of receptors [%*E-2]'
```

```

CONSTANT tp = 1.          '$Time of receptors exposure to FR [h]
CONSTANT a  = 0.075       '$Receptor population response constant
CONSTANT TSTOP = 2.       '$Length of experiment [h]
CONSTANT TME = 1.         '$Time to maximum effect [h]
CONSTANT POINTS= 1.       '$Number of communication intervals
      Ft = tp/TME         '$Fraction of max time [ratio]
'Parameters for dose-response simulation

CONSTANT CMIN = 100.      '$Starting concentration [uM]
CONSTANT CMAX = 1000.     '$Final concentration [uM]
CONSTANT CDELTA = 100.    '$Concentration interval [uM]

'Miscellaneous parameters
INTEGER I,ND
CINT = TSTOP/POINTS      '$Interval for saving data to *.RRR file
REAL DOS(1000),PROB(1000),DOSC(1000)
'arrays of data saved for plotting PROBability vs DOSe
'Initialize variables for dose-response calculation
PCONC=0. $ FRad=0. $ Inh=1.0
C0 = CMIN-CDELTA
ND = INT((CMAX - CMIN)/CDELTA) + 1
I = 1

'Start of dose-response loop
RESTART..C0=C0+cdelta
END '$End of INITIAL section
'-----

DYNAMIC '$Beginning of execution section of program
'-----

      FR = SQRT(ki*C0/kt)      '$Concentration of free radicals [uM]
'-----
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^DETERMINISTIC MODULE^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
      In = I0 * exp(-kd*FR*tp) '$Amount of active receptors remaining
                                'after exposure to FR for time = tp
'-----
      TERMT(T.GE.TSTOP)      '$Stop simulation when T >= TSTOP
'-----

END          '$End of dynamic section

TERMINAL    '$Post-execution section of program

PCONC = C0          '$Save current concentration [uM]
FRad = FR           '$Save conc. of free radicals [uM]
Inh = In            '$Relative amount of active receptors
DOS(I) = FRad       '$Save I-th FR concentration to array
DOSC(I)=PCONC       '$Save I-th chemical conc. to array
I = I + 1
CALL LOGD(.FALSE.)
IF (C0.lt.cmax) goto restart '$Restart to initial unless done

'-----
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^STOCHASTIC MODULE^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
'*****START FORTRAN SUBROUTINE*****

PROCEDURAL (PROB = ND,DOS,Ft)
      CALL OMPHI (ND,DOS,PROB,Ft)
END          '$End of procedural

```

```

PROCEDURAL(DOSC,PROB)
  DO 20 K = 1,ND
    WRITE(41,30) DOSC(K),PROB(K)
20..CONTINUE
30..FORMAT( F9.3,2X,F6.4)
    WRITE(41,40)
40..FORMAT('  END')
END
END      '$End of terminal section'
END      '$End of program'

SUBROUTINE OMPHI(ND,D1,PROB,Ft)
C
C  OMPHI FINDS 1 - CUMMULATIVE GAUSSIAN DISTRIBUTION.
C
  INTEGER I,ND,NDMAX
  PARAMETER(NDMAX=1000)
  REAL M,SD,D,S1,S2,N,Ft,PROB(NDMAX),D1(NDMAX)
C
C  VARIABLE      TYPE      DESCRIPTION
C    I            INTEGER  INDEX VARIABLE
C    ND           INTEGER  NUMBER OF DOSES
C    NDMAX        INTEGER  MAX NUMBER OF DOSES
C    Ft           REAL     FRACTION OF TIME TO MAX EFFECT
C    M            REAL     MEAN OF DOSE
C    SD           REAL     STANDARD DEVIATION OF DOSE
C    D            REAL     DOSE VALUE
C    D1           REAL     ARRAY OF DOSE VALUES
C    PROB         REAL     ARRAY OF RESULTS OF 1 - CUM. GAUSS. DIST.
C
C  CALCULATES THE MEAN AND STANDARD DEVIATION OF DOSE.
C
  S1 = 0.0
  S2 = 0.0
  DO 10 I = 1,ND
    D = D1(I)
    S1 = S1 + D
    S2 = S2 + D*D
10 CONTINUE
  N = FLOAT(ND)
  M = S1/N
  SD = SQRT((S2 - S1*S1/N)/(N - 1))
C
C  FINDS AND OUTPUTS THE PROBABILITY OF CUMMULATIVE GAUSSIAN.
C
  DO 20 I = 1,ND
    D = D1(I)
    PROB(I) = 1.0 - Ft * PHI(M,SD,D)
20 CONTINUE
  RETURN
END
FUNCTION PHI(M,SD,D)
C
C  PHI FINDS THE CUMMULATIVE GAUSSIAN DISTRIBUTION USING THE
C  ERROR FUNCTION AND THE COMPLEMENTARY ERROR FUNCTION.
C
  REAL M,SD,D,X
C
C  VARIABLE      TYPE      DESCRIPTION
C    M            REAL     INPUT MEAN OF DOSE(D)
C    SD           REAL     INPUT STANDARD DEVIATION OF DOSE(D)

```

```

C          D          REAL      INPUT DOSE
C          X          REAL      INTERNAL VARIABLE
C
X = (D - M)/SD
X = X/SQRT(2.0)
IF (X .GE. 0.0) THEN
    PHI = (1.0 + ERF(X))/2.0
ELSE
    PHI = ERFC(-X)/2.0
ENDIF
RETURN
END
FUNCTION erf(x)
C
C   ERF FINDS THE ERROR FUNCTION.
C
C   USES gammp
C
REAL erf,x,gammp
if(x.lt.0.)then
    erf=-gammp(.5,x**2)
else
    erf=gammp(.5,x**2)
endif
return
END
FUNCTION gammp(a,x)
C
C   GAMMP FINDS THE INCOMPLETE GAMMA FUNCTION P(a,x).
C
REAL a,gammp,x
C
C   USES gcf,gser
C
REAL gammcf,gamser,gln
if(x.lt.0..or.a.le.0.)pause 'bad arguments in gammp'
if(x.lt.a+1.)then
    call gser(gamser,a,x,gln)
    gammp=gamser
else
    call gcf(gammcf,a,x,gln)
    gammp=1.-gammcf
endif
return
END
SUBROUTINE gcf(gammcf,a,x,gln)
C
C   GCF RETURNS THE INCOMPLETE GAMMA FUNCTION Q(a,x) EVALUATED
C   BY ITS CONTINUED FRACTION REPRESENTATION AS GAMMCF. IT
C   ALSO RETURNS lnGAMMA(a) AS GLN,
C
INTEGER ITMAX
REAL a,gammcf,gln,x,EPS,FPMIN
PARAMETER (ITMAX=100,EPS=3.e-7,FPMIN=1.e-30)
C
C   USES gammln
C
INTEGER i
REAL an,b,c,d,del,h,gammln
gln=gammln(a)
b=x+1.-a

```

```

c=1./FPMIN
d=1./b
h=d
do 11 i=1,ITMAX
  an=-i*(i-a)
  b=b+2.
  d=an*d+b
  if(abs(d).lt.FPMIN)d=FPMIN
  c=b+an/c
  if(abs(c).lt.FPMIN)c=FPMIN
  d=1./d
  del=d*c
  h=h*del
  if(abs(del-1.).lt.EPS)goto 1
11 continue
pause 'a too large, ITMAX too small in gcf'
1 gammcf=exp(-x+a*log(x)-gln)*h
return
END
SUBROUTINE gser(gamser,a,x,gln)
C
C GSER RETURNS THE INCOMPLETE GAMMA FUNCTION P(a,x) EVALUATED
C BY ITS SERIES REPRESENTATION AS GAMSER. IT ALSO RETURNS
C lnGAMMA(a) AS GLN.
C
  INTEGER ITMAX,n
  REAL a,gamser,gln,x,EPS,ap,del,sum,gammln
  PARAMETER (ITMAX=100,EPS=3.e-7)
C
C USES gammln
C
  gln=gammln(a)
  if(x.le.0.)then
    if(x.lt.0.)pause 'x < 0 in gser'
    gamser=0.
    return
  endif
  ap=a
  sum=1./a
  del=sum
  do 11 n=1,ITMAX
    ap=ap+1.
    del=del*x/ap
    sum=sum+del
    if(abs(del).lt.abs(sum)*EPS)goto 1
11 continue
pause 'a too large, ITMAX too small in gser'
1 gamser=sum*exp(-x+a*log(x)-gln)
return
END
FUNCTION gammln(xx)
C
C GAMMLN RETURNS THE VALUE ln[GAMMA(xx)] FOR xx > 0.
C
  REAL gammln,xx
  INTEGER j
  DOUBLE PRECISION ser,stp,tmp,x,y,cof(6)
  SAVE cof,stp
  DATA cof,stp/76.18009172947146d0,-86.50532032941677d0,
*24.01409824083091d0,-1.231739572450155d0,
*.1208650973866179d-2,

```

```

      *- .5395239384953d-5,2.5066282746310005d0/
      x=xx
      y=x
      tmp=x+5.5d0
      tmp=(x+0.5d0)*log(tmp)-tmp
      ser=1.000000000190015d0
      do 11 j=1,6
        y=y+1.d0
        ser=ser+cof(j)/y
11    continue
      gammaln=tmp+log(stp*ser/x)
      return
      END
      FUNCTION erfc(x)
C
C      ERFC FINDS COMPLIMENTARY ERROR FUNCTION.
C
      REAL erfc,x
C
C      USES gammp,gammq
C
      REAL gammp,gammq
      if(x.lt.0.)then
        erfc=1.+gammp(.5,x**2)
      else
        erfc=gammq(.5,x**2)
      endif
      return
      END
      FUNCTION gammq(a,x)
C
C      GAMMQ RETURNS THE INCOMPLETE GAMMA FUNCTION  $Q(a,x) = 1 -$ 
C       $P(a,x)$ .
C
      REAL a,gammq,x
C
C      USES gcf,gser
C
      REAL gammcf,gamser,gln
      if(x.lt.0..or.a.le.0.)pause 'bad arguments in gammq'
      if(x.lt.a+1.)then
        call gser(gamser,a,x,gln)
        gammq=1.-gamser
      else
        call gcf(gammcf,a,x,gln)
        gammq=gammcf
      endif
      return
      END

```

• Command files and graphics for deterministic and stochastic modules **BBDR Sub-Model *.CMD FILES**

```

' ^^^^^^^^^^^^^^^^^^^^^^DATA FROM LITERATURE^^^^^^^^^^^^^^^^^^^^^^^^^'
' -----Steel-Goodwin et al., (1995)-----'
PROCED FIG8
'kinetics of FRAD production from TCE in precision cut'
'mouse liver slices'
PREPAR 'CLEAR',Pconc, FRad

```

```

SET TITLE = 'BBPD Module: Effect of TCE on Generation of Free Radicals'
SET ki=900,kt=200,cmin=1.,cdelt=1.,cmax=40.,tp=0.333
SET TSTOP=0.333,NRWITG=.T., TME=0.333
'data normalized to physiological background=0.'

```

```

'uM/g      uM/g'
DATA
Pconc      FRad
0.          0.
9.85       3.5
18.9       9.4
32.8       11.9
37.15      15.
END          '$end of data'
START
PLOT FRAD, 'TAG'='- FR CONCENTR. (um/g)', 'XTAG'=' - TCE (um/g)'
END          '$end of Linda'

```

'-----Vroegop, et al. (1995)-----'

```

PROCED FIG19A
'effect of cumene hydroperoxide on amino acid'
'transport 1 = 19000 cpm'
SET TITLE = 'BBDR: Effect of Cum.OOH on AA Transporter'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=10.,cdelt=10.,cmax=1000.,TP=1.,TSTOP=2.
SET NRWITG=.T.,ki=100,kt=200,kd=0.075, TME=1.

```

```

'uM      % Control'
DATA
Pconc    Inh
0.        1.
1.        0.84
3.3       0.91
10.       0.95
33.       0.71
50.       0.69
80.       0.57
130.      0.52
200.      0.47
330.      0.37
1000.     0.22
END        '$end of data'
START
PLOT Inh, 'lo'=0., 'TAG'=' - ACT. AA TRANSPORTERS' ...
      'XTAG' = ' - CUM.OOH (uM)'
END        '$end of CHDOSEAA'

```

```

PROCED FIG19B
'effect of H2O2 on glucose'
'transporter 1 = 25250 cpm'
SET TITLE = 'BBDR: Effect of H2O2 on Glucose Transporter'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=100.,cdelt=100.,cmax=10000.,TP=1.,TSTOP=2.
SET NRWITG=.T.,ki=18,kt=200,kd=0.1, TME=1.

```

```

'uM      % Control'
DATA
Pconc    Inh
0.        1.
3.3       0.92
10.       0.95

```

```

33.      0.89
100.     0.76
330.     0.57
1000.    0.48
3300.    0.22
10000.   0.05
33000.   0.04
END      '$end of data'
START
PLOT Inh,'lo'=0., 'TAG'=' - ACT. GLUC TRANSPORTERS' ...
      'xhi'=10000,'XTAG' = ' - H2O2 (uM)'
END      '$end of H2O2DG'

'-----Heffetz et al. (1990)-----'
PROCED FIG19C
'effect of H2O2 on protein Tyr phosphatase'
'Tyr Pase activity measured as [32P] remaining'
'in [32P]poly-(Glu,Tyr)'
SET TITLE = 'BBDR: Effect of H2O2 on PTyrPase'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=0.01,cdelt=10.,cmax=500.,TP=0.3333,TSTOP=0.42
SET NRWITG=.T.,ki=18,kt=200,kd=1.,TME=0.3333

'mM      % Control'
DATA
Pconc    Inh
0.        1.
10.       0.4953
20.       0.7143
25.       0.5333
30.       0.5143
50.       0.3143
100.      0.1430
200.      0.1143
300.      0.0476
500.      0.00952
END      '$end of data'
START
PLOT Inh,'lo'=0.,'TAG'=' - ACT. PTPase'...
      'XTAG' = ' - H2O2 (uM)'
END      '$end of H2O2PTP'

'-----Hecht and Zick (1992)-----'
PROCED FIG19D
'effect of vanadate on protein Tyr phosphatase'
'Tyr Pase activity measured as [32P] remaining'
'in [32P]poly-(Glu,Tyr)'
SET TITLE = 'BBDR: Effect of Vanad. on PTyrPase'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=0.1,cdelt=10.,cmax=1000.,TP=0.5,TSTOP=0.633
SET NRWITG=.T.,ki=18,kt=200,kd=1.,TME=0.7

'uM      % Control'
DATA
Pconc    Inh
0.        1.
1.        0.529
10.       0.456
100.      0.191
1000.     0.294
END      '$end of data'

```

```

START
PLOT Inh, 'lo'=0., 'xlo'=0., 'TAG'=' - ACT. PTPase'...
      'XTAG' = ' - VANAD (uM)'
END      $'end of VANADTP'

      \-----Vroegop, et al. (1995)-----/
PROCED FIG20A
'effect of 6-OH dopamine on amino acid transport 1 = 5600 cpm'
PREPAR 'CLEAR', Pconc, Inh
SET TITLE = 'BBDR: Effects of 6-OH Dopamine on AA Transporter'
SET TP=1., TSTOP=2., ki=200, kd=0.075, cmin=10., cdelt=3., cmax=300.
SET NRWITG=.T., Kt=200, TME=1.
'uM      % Control'
DATA
Pconc      Inh
0.          1.
10.         1.
20.         0.916
40.         1.
60.         0.916
80.         0.8779
90.         0.8321
100.        0.4351
200.        0.2214
300.        0.2137
END          $'end of data'
START
PLOT Inh, 'lo'=0., 'TAG'=' - ACT. AA TRANSPORTERS' ...
      'XTAG' = ' - 6-OH DOPAMINE (uM)'
END          $'end of 6OHDAA'

PROCED FIG20B
'effect of H2O2 on amino acid transport 1 = 6350 cpm'
SET TITLE = 'BBDR: Effect of H2O2 on AA Transporter'
PREPAR 'CLEAR', Pconc, Inh
SET cmin=10., cdelt=1., cmax=100., TP=1., TSTOP=2.
SET NRWITG=.T., ki=18, kt=200, kd=0.075, TME=1.
'uM      % Control'
DATA
Pconc      Inh
0.          1.
0.33       1.0
10.         0.86
33.         0.56
55.         0.42
100.        0.34
END          $'end of data'
START
PLOT Inh, 'lo'=0., 'TAG'=' - ACT. AA TRANSPORTERS' ...
      'XTAG' = ' - H2O2 (uM)'
END          $'end of H2O2DAA'

PROCED FIG20C
'effect of 6-OH dopamine on mitochondria staining 1 = 0.51 OD'
SET TITLE = 'BBDR: Effect of 6-OH Dopamine on Mitochondria'
PREPAR 'CLEAR', Pconc, Inh
SET kd=0.05, cmin=40., cdelt=2., cmax=200., TP=1., TSTOP=2.
SET NRWITG=.T., ki=200, kt=200, TME=2.04
'uM      % Control'

```

```

DATA
Pconc      Inh
0.          1.
10.         1.0
20.         1.0
40.         1.0
60.         0.982
80.         0.927
90.         0.918
100.        0.795
200.        0.498
300.        0.502
500.        0.466
END          '$'end of data'
START
PLOT Inh,'lo'=0., 'TAG'=' - ACT. MITOCHONDRIA' ...
      'XTAG' = ' - 6-OH DOPAMINE (uM)'
END          '$'end of 6OHDMIT'

PROCED FIG20D
'effect of H2O2 on mitochondria staining 1 = 0.49 OD'
SET TITLE = 'BBDR: Effect of H2O2 on Mitochondria'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=10.,cdelt=1.,cmax=100.,TP=1.,TSTOP=2.
SET NRWITG=.T.,ki=18,kt=200,kd=0.05, TME=1.

```

```

'uM          % Control'
DATA
Pconc      Inh
0.          1.
0.33       0.97
10.         1.
18.         0.95
33.         0.69
55.         0.55
100.        0.50
END          '$'end of data'
START
PLOT Inh,'lo'=0., 'TAG'=' - ACT. MITOCHONDRIA' ...
      'XTAG' = ' - H2O2 (uM)'
END          '$'end of H2O2DM'

```

```

'-----Heffetz et al. (1990)-----'
PROCED FIG21A
'effect of pervanadate on protein Tyr phosphatase'
'in the presence of 2 mM H2O2'
'Tyr Pase activity measured as [32P] remaining'
'in [32P]poly-(Glu,Tyr)'
SET TITLE = 'BBDR: Effect of PerVanadate on PTyrPase'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=0.1,cdelt=10.,cmax=1000.,TP=0.333,TSTOP=0.42
SET NRWITG=.T.,ki=18,kt=200,kd=1.,TME=0.333

```

```

'uM          % Control'
DATA
Pconc      Inh
0.01       1.
1.          0.9467
10.         0.6
100.        0.3933
1000.       0.1267

```

```

END          '$end of data'
START
PLOT Inh,'lo'=0.,'xlog','xlo'=0.01,'TAG'=' - ACT. PTPase'...
      'XTAG' = ' - PERVAN (uM)'
END          '$end of VANADTP'

'-----Vroegop, et al. (1995)-----'
PROCED FIG21B
'effect of CumOOH on mitochondria staining 1 = 0.49 OD'
SET TITLE = 'BBDR: Effect of Cum.OOH on Mitochondria'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=10.,cdelt=10.,cmax=1000.,TP=1.,TSTOP=2.
SET NRWITG=.T.,ki=100,kt=200,kd=0.05, TME=4.

'uM          % Control'
DATA
Pconc      Inh
0.          1.
3.          1.0
10.         1.
33.         0.95
100.        0.91
330.        1.0
1000.       0.79
END          '$end of data'
START
PLOT Inh,'lo'=0., 'TAG'=' - ACT. MITOCHONDRIA' ...
      'xlog','xlo'=1,'XTAG' = ' - Log CUM.OOH (uM)'
END          '$end of CHDMIT'

PROCED FIG22
'effect of cumene hydroperoxide on glucose'
'transporter 1 = 18300 cpm'
SET TITLE = 'BBDR: Effect of Cum.OOH on Glucose Transporter'
PREPAR 'CLEAR',Pconc,Inh
SET cmin=10.,cdelt=2.,cmax=200.,TP=1.,TSTOP=2.
SET NRWITG=.T.,ki=100,kt=200,kd=0.1, TME=1.

'uM          % Control'
DATA
Pconc      Inh
0.          1.
4.5         0.97
10.         0.90
20.         0.82
45.         0.62
100.        0.46
125.        0.38
150.        0.30
200.        0.19
END          '$end of data'
START
PLOT Inh,'lo'=0., 'TAG'=' - ACT. GLUC TRANSPORTERS' ...
      'XTAG' = ' - CUM.OOH (uM)'
END          '$end of CHDG'

'-----Theoretical simulation-----'
PROCED FIG26A
'theoretical BBDR deterministic simulation with the range of TCE'
'local doses corresponding to ethane exhalation experiments'
SET TITLE = 'BBDR: Simulated Effects of TCE on PTyrPase Activity'

```

```

PREPAR 'CLEAR',PCONC, Inh
SET cmin=0.5,cdelt=0.5,cmax=50.,TP=0.5,TSTOP=0.633,TME=0.5
SET NRWITG=.T., ki=900., kt=200., kd=1.
START

```

```

'SET TME=1.'
'START'

```

```

'SET TME=2.'
'START'
PLOT Inh,'char'=' ','lo'=0.,'tag'='- % ACT. PTPase'...
      'xhi'=50.,'xtag'='- TCE (um/g)'
END      '$'end of TCEPTP'

```

BBDR Stochastic Array Graphics *.CSL FILE

PROGRAM: PLOT FOR GRAFGAUS

```

'Program allows to plot GRAPHG.CMD files created by GRAFGAUS
'Final version 8/28/95

```

INITIAL

```

variable N = 0.      '$defines independent variable N = PCONC
CONSTANT Nmax=100.$'defines the maximum PCONC value in plot
CONSTANT CINT= 1.  '$reports at every whole unit of PCONC
CONSTANT FRAD= 0.  '$sham value for another independent variable'
END

```

DYNAMIC

```

PCONC = N
PROB = 0.      '$sham values for dependent variables
ACT = 0.
END

```

```

TERMT (N.GE.Nmax)  '$Stop at maximum dose

```

END

Output of stochastic module, created by *BBDR Sub-Model:

BBDR Array Graphics *.CMD FILE

```

'FIG 19 A'
PROC NDATA
prepar pconc,prob
set title='BBDR: Effect of Cum.OOH on AA Transporter'
set Nmax=1000.
DATA
PCONC      PROB
      0.      1.      INITIAL
10.000  0.9927
20.000  0.9883
30.000  0.9834
40.000  0.9781

```

50.000	0.9723
60.000	0.9659
70.000	0.9591
80.000	0.9517
90.000	0.9439
100.000	0.9356
110.000	0.9269
120.000	0.9177
130.000	0.9082
140.000	0.8982
150.000	0.8879
160.000	0.8772
170.000	0.8661
180.000	0.8548
190.000	0.8431
200.000	0.8312
210.000	0.8190
220.000	0.8066
230.000	0.7940
240.000	0.7813
250.000	0.7683
260.000	0.7552
270.000	0.7419
280.000	0.7286
290.000	0.7152
300.000	0.7017
310.000	0.6881
320.000	0.6745
330.000	0.6609
340.000	0.6472
350.000	0.6336
360.000	0.6200
370.000	0.6065
380.000	0.5930
390.000	0.5796
400.000	0.5662
410.000	0.5530
420.000	0.5398
430.000	0.5268
440.000	0.5139
450.000	0.5011
460.000	0.4885
470.000	0.4760
480.000	0.4636
490.000	0.4514
500.000	0.4394
510.000	0.4276
520.000	0.4159
530.000	0.4045
540.000	0.3932
550.000	0.3821
560.000	0.3712
570.000	0.3605
580.000	0.3500

```

590.000  0.3397
600.000  0.3296
610.000  0.3197
620.000  0.3100
630.000  0.3005
640.000  0.2913
650.000  0.2822
660.000  0.2734
670.000  0.2647
680.000  0.2562
690.000  0.2480
700.000  0.2400
710.000  0.2321
720.000  0.2245
730.000  0.2170
740.000  0.2098
750.000  0.2027
760.000  0.1958
770.000  0.1891
780.000  0.1826
790.000  0.1763
800.000  0.1702
810.000  0.1642
820.000  0.1584
830.000  0.1528
840.000  0.1473
850.000  0.1420
860.000  0.1369
870.000  0.1319
880.000  0.1271
890.000  0.1224
900.000  0.1179
910.000  0.1135
920.000  0.1093
930.000  0.1052
940.000  0.1012
950.000  0.0974
960.000  0.0937
970.000  0.0901
980.000  0.0866
990.000  0.0833
1000.000 0.0800
END      '$end of data'
START
PLOT PROB, 'lo'=0, 'hi'=1, 'xhi'=1000, 'xtag'=' -CUM.OOH (uM)'
END      '$END of file'

```

```

'FIG 19 B'
PROC NDATA
prepar pconc,prob
set title='BBDR: Effect of H2O2 on Glucose Transporter'
set Nmax=10000.
DATA
PCONC      PROB

```

0.	1.	INITIAL
100.000	0.9927	
200.000	0.9883	
300.000	0.9834	
400.000	0.9781	
500.000	0.9723	
600.000	0.9659	
700.000	0.9591	
800.000	0.9517	
900.000	0.9439	
1000.000	0.9356	
1100.000	0.9269	
1200.000	0.9177	
1300.000	0.9082	
1400.000	0.8982	
1500.000	0.8879	
1600.000	0.8772	
1700.000	0.8661	
1800.000	0.8548	
1900.000	0.8431	
2000.000	0.8312	
2100.000	0.8190	
2200.000	0.8066	
2300.000	0.7940	
2400.000	0.7813	
2500.000	0.7683	
2600.000	0.7552	
2700.000	0.7419	
2800.000	0.7286	
2900.000	0.7152	
3000.000	0.7016	
3100.000	0.6881	
3200.000	0.6745	
3300.000	0.6609	
3400.000	0.6472	
3500.000	0.6336	
3600.000	0.6200	
3700.000	0.6065	
3800.000	0.5930	
3900.000	0.5796	
4000.000	0.5662	
4100.000	0.5530	
4200.000	0.5398	
4300.000	0.5268	
4400.000	0.5139	
4500.000	0.5011	
4600.000	0.4885	
4700.000	0.4760	
4800.000	0.4636	
4900.000	0.4514	
5000.000	0.4394	
5100.000	0.4276	
5200.000	0.4159	
5300.000	0.4045	

5400.000	0.3932
5500.000	0.3821
5600.000	0.3712
5700.000	0.3605
5800.000	0.3500
5900.000	0.3397
6000.000	0.3296
6100.000	0.3197
6200.000	0.3100
6300.000	0.3005
6400.000	0.2913
6500.000	0.2822
6600.000	0.2734
6700.000	0.2647
6800.000	0.2562
6900.000	0.2480
7000.000	0.2400
7100.000	0.2321
7200.000	0.2245
7300.000	0.2170
7400.000	0.2098
7500.000	0.2027
7600.000	0.1958
7700.000	0.1891
7800.000	0.1826
7900.000	0.1763
8000.000	0.1702
8100.000	0.1642
8200.000	0.1584
8300.000	0.1528
8400.000	0.1473
8500.000	0.1420
8600.000	0.1369
8700.000	0.1319
8800.000	0.1271
8900.000	0.1224
9000.000	0.1179
9100.000	0.1135
9200.000	0.1093
9300.000	0.1052
9400.000	0.1012
9500.000	0.0974
9600.000	0.0937
9700.000	0.0901
9800.000	0.0866
9900.000	0.0833

10000.000 0.0800

END \$'End of data'

START

PLOT PROB, 'lo'=0, 'hi'=1, 'xhi'=10000, ...

'xtag'=' -H2O2 (uM)'

END \$'END of file'

```

'FIG 19 C'
PROC NDATA
  prepar pconc,prob
  set title='BBDR: Effect of H2O2 on PTyrPase'
  set Nmax=500.

```

```

DATA
PCONC      PROB      INITIAL
    0.      1.
  0.010  0.9959
 10.010  0.9817
 20.010  0.9680
 30.010  0.9525
 40.010  0.9353
 50.010  0.9163
 60.010  0.8958
 70.010  0.8740
 80.010  0.8509
 90.010  0.8269
100.010  0.8020
110.010  0.7764
120.010  0.7503
130.010  0.7238
140.010  0.6970
150.010  0.6702
160.010  0.6434
170.010  0.6167
180.010  0.5902
190.010  0.5641
200.010  0.5384
210.010  0.5131
220.010  0.4884
230.010  0.4643
240.010  0.4409
250.010  0.4181
260.010  0.3960
270.010  0.3747
280.010  0.3541
290.010  0.3343
300.010  0.3153
310.010  0.2971
320.010  0.2796
330.010  0.2629
340.010  0.2470
350.010  0.2318
360.010  0.2174
370.010  0.2037
380.010  0.1906
390.010  0.1783
400.010  0.1666
410.010  0.1556
420.010  0.1452
430.010  0.1354
440.010  0.1261
450.010  0.1174

```

```

460.010  0.1093
470.010  0.1016
480.010  0.0944
490.010  0.0876
END      '$End of data'
START
PLOT PROB, 'lo'=0, 'hi'=1., 'xhi'=500, 'xtag'=' -H2O2 (uM)'
END      '$End of file'

```

```

'FIG 19 D'
PROC NDATA
prepar pconc, prob
set title='BBDR: Effect of Vanad. on PTyrPase'
set Nmax=1000.

```

```

DATA
PCONC      PROB
  0.        1.      INITIAL
  0.100    0.9976
  10.100   0.9930
  20.100   0.9890
  30.100   0.9848
  40.100   0.9803
  50.100   0.9754
  60.100   0.9702
  70.100   0.9646
  80.100   0.9587
  90.100   0.9525
 100.100   0.9460
 110.100   0.9391
 120.100   0.9320
 130.100   0.9246
 140.100   0.9170
 150.100   0.9091
 160.100   0.9011
 170.100   0.8928
 180.100   0.8843
 190.100   0.8756
 200.100   0.8668
 210.100   0.8578
 220.100   0.8487
 230.100   0.8395
 240.100   0.8302
 250.100   0.8207
 260.100   0.8113
 270.100   0.8017
 280.100   0.7921
 290.100   0.7825
 300.100   0.7728
 310.100   0.7631
 320.100   0.7535
 330.100   0.7438
 340.100   0.7342
 350.100   0.7246
 360.100   0.7150

```

370.100	0.7055
380.100	0.6960
390.100	0.6866
400.100	0.6773
410.100	0.6680
420.100	0.6588
430.100	0.6498
440.100	0.6408
450.100	0.6319
460.100	0.6232
470.100	0.6145
480.100	0.6060
490.100	0.5976
500.100	0.5893
510.100	0.5811
520.100	0.5731
530.100	0.5652
540.100	0.5574
550.100	0.5498
560.100	0.5423
570.100	0.5350
580.100	0.5278
590.100	0.5207
600.100	0.5138
610.100	0.5070
620.100	0.5004
630.100	0.4939
640.100	0.4875
650.100	0.4813
660.100	0.4753
670.100	0.4694
680.100	0.4636
690.100	0.4579
700.100	0.4524
710.100	0.4471
720.100	0.4419
730.100	0.4368
740.100	0.4318
750.100	0.4270
760.100	0.4223
770.100	0.4177
780.100	0.4132
790.100	0.4089
800.100	0.4047
810.100	0.4006
820.100	0.3967
830.100	0.3928
840.100	0.3891
850.100	0.3854
860.100	0.3819
870.100	0.3785
880.100	0.3752
890.100	0.3720
900.100	0.3689

```

910.100  0.3658
920.100  0.3629
930.100  0.3601
940.100  0.3574
950.100  0.3547
960.100  0.3521
970.100  0.3497
980.100  0.3473
990.100  0.3450
END      '$END of data'
START
PLOT PROB, 'lo'=0, 'hi'=1, 'xtag'=' -VANAD (uM)'
END      '$end of file'

```

'FIG 20 A'

PROC NDATA

Prepar Pconc, Prob

Set title='BBDR: Effect of 6-OH Dopamine on AA Transporter'

Set Nmax=300.

DATA

PCONC	PROB
0.0	1. INITIAL
10.000	0.9849
20.000	0.9670
30.000	0.9437
40.000	0.9154
50.000	0.8825
60.000	0.8459
70.000	0.8060
80.000	0.7639
90.000	0.7200
100.000	0.6752
110.000	0.6301
120.000	0.5853
130.000	0.5412
140.000	0.4982
150.000	0.4568
160.000	0.4172
170.000	0.3796
180.000	0.3442
190.000	0.3109
200.000	0.2800
210.000	0.2513
220.000	0.2249
230.000	0.2007
240.000	0.1786
250.000	0.1585
260.000	0.1402
270.000	0.1238
280.000	0.1090
290.000	0.0958
300.000	0.0840

```

END      '$End of Data'
START

```

```

PLOT PROB,'lo'=0,'hi'=1.,'tag'=' -Act. AA Transp'...
      'xhi'=300, 'xtag'=' - 6-OH DOPAMINE (uM)'
END      '$'End of File'

```

'FIG 20 B'

PROC NDATA

prepar pconc,prob

set title='BBDR: Effect of H2O2 on AA Transporter'

set nmax=100.

DATA

PCONC	PROB	INITIAL
0.	1.	
10.000	0.9816	
11.000	0.9776	
12.000	0.9732	
13.000	0.9683	
14.000	0.9629	
15.000	0.9570	
16.000	0.9506	
17.000	0.9437	
18.000	0.9362	
19.000	0.9283	
20.000	0.9199	
21.000	0.9110	
22.000	0.9016	
23.000	0.8917	
24.000	0.8814	
25.000	0.8706	
26.000	0.8594	
27.000	0.8478	
28.000	0.8358	
29.000	0.8234	
30.000	0.8107	
31.000	0.7977	
32.000	0.7843	
33.000	0.7707	
34.000	0.7568	
35.000	0.7427	
36.000	0.7284	
37.000	0.7139	
38.000	0.6993	
39.000	0.6845	
40.000	0.6696	
41.000	0.6547	
42.000	0.6396	
43.000	0.6246	
44.000	0.6095	
45.000	0.5944	
46.000	0.5794	
47.000	0.5644	
48.000	0.5494	
49.000	0.5346	
50.000	0.5198	
51.000	0.5052	

```

52.000 0.4907
53.000 0.4764
54.000 0.4622
55.000 0.4482
56.000 0.4344
57.000 0.4208
58.000 0.4074
59.000 0.3943
60.000 0.3813
61.000 0.3686
62.000 0.3562
63.000 0.3440
64.000 0.3320
65.000 0.3203
66.000 0.3089
67.000 0.2977
68.000 0.2868
69.000 0.2762
70.000 0.2658
71.000 0.2557
72.000 0.2459
73.000 0.2364
74.000 0.2271
75.000 0.2181
76.000 0.2094
77.000 0.2009
78.000 0.1927
79.000 0.1848
80.000 0.1771
81.000 0.1696
82.000 0.1624
83.000 0.1555
84.000 0.1488
85.000 0.1423
86.000 0.1360
87.000 0.1300
88.000 0.1242
89.000 0.1186
90.000 0.1133
91.000 0.1081
92.000 0.1031
93.000 0.0983
94.000 0.0937
95.000 0.0893
96.000 0.0851
97.000 0.0810
98.000 0.0772
99.000 0.0734
100.000 0.0699
END $'End of data'
START
PLOT PROB,'lo'=0,'hi'=1.,'xhi'=100
END $'END of file'

```

```

'FIG 20 C'
PROC NDATA
  prepar pconc, prob
  set title='BBDR: Effect of 6-OH Dopamine on Mitochondria'
  SET NMAX=200.

```

```

DATA
  PCONC      PROB      INITIAL
    0.        1.
  40.000    0.9826
  50.000    0.9672
  60.000    0.9455
  70.000    0.9178
  80.000    0.8852
  90.000    0.8489
 100.000    0.8106
 110.000    0.7720
 120.000    0.7344
 130.000    0.6990
 140.000    0.6667
 150.000    0.6379
 160.000    0.6129
 170.000    0.5917
 180.000    0.5740
 190.000    0.5595
 200.000    0.5478

```

```

END
START
PLOT PROB, 'lo'=0., 'hi'=1., 'tag'=' -ACT Mito'...
      'xhi'=200., 'xtag'=' -6-OH DOPAMINE (uM)'
END

```

```

'FIG 20 D'
PROC NDATA
  prepar pconc, prob
  set title='BBDR: Effect of H2O2 on Mitochondria'
  set Nmax=100.

```

```

DATA
  PCONC      PROB      INITIAL
    0.        1.
  10.000    0.9608
  20.000    0.8800
  30.000    0.7663
  40.000    0.6362
  50.000    0.5061
  60.000    0.3874
  70.000    0.2867
  80.000    0.2059
  90.000    0.1439
 100.000    0.0982

```

```

END      '$end of data'
START
PLOT PROB, 'lo'=0., 'hi'=1., 'xhi'=100, 'xtag'=' -H2O2 (uM)'
END      '$END of file'

```

```

'FIG 21 A'
PROC NDATA
prepar pconc,prob
set title='BBDR: Effect of PerVanadate on PTyrPase'
set Nmax=1000
DATA
PCONC      PROB      INITIAL
  0.01      1.
  0.100     0.9966
 10.100     0.9902
 20.100     0.9846
 30.100     0.9788
 40.100     0.9724
 50.100     0.9656
 60.100     0.9583
 70.100     0.9505
 80.100     0.9422
 90.100     0.9335
100.100     0.9244
110.100     0.9148
120.100     0.9048
130.100     0.8945
140.100     0.8838
150.100     0.8728
160.100     0.8615
170.100     0.8499
180.100     0.8380
190.100     0.8258
200.100     0.8135
210.100     0.8009
220.100     0.7882
230.100     0.7753
240.100     0.7622
250.100     0.7490
260.100     0.7358
270.100     0.7224
280.100     0.7090
290.100     0.6955
300.100     0.6819
310.100     0.6684
320.100     0.6549
330.100     0.6413
340.100     0.6278
350.100     0.6144
360.100     0.6010
370.100     0.5877
380.100     0.5744
390.100     0.5612
400.100     0.5482
410.100     0.5352
420.100     0.5224
430.100     0.5097
440.100     0.4971
450.100     0.4847

```

460.100	0.4724
470.100	0.4603
480.100	0.4484
490.100	0.4366
500.100	0.4250
510.100	0.4135
520.100	0.4023
530.100	0.3912
540.100	0.3804
550.100	0.3697
560.100	0.3592
570.100	0.3489
580.100	0.3389
590.100	0.3290
600.100	0.3193
610.100	0.3098
620.100	0.3005
630.100	0.2914
640.100	0.2826
650.100	0.2739
660.100	0.2654
670.100	0.2571
680.100	0.2490
690.100	0.2411
700.100	0.2334
710.100	0.2259
720.100	0.2186
730.100	0.2115
740.100	0.2045
750.100	0.1978
760.100	0.1912
770.100	0.1848
780.100	0.1785
790.100	0.1725
800.100	0.1666
810.100	0.1609
820.100	0.1553
830.100	0.1499
840.100	0.1447
850.100	0.1396
860.100	0.1347
870.100	0.1299
880.100	0.1253
890.100	0.1208
900.100	0.1164
910.100	0.1122
920.100	0.1081
930.100	0.1041
940.100	0.1003
950.100	0.0966
960.100	0.0930
970.100	0.0895
980.100	0.0862
990.100	0.0829

```

END      '$END of data'
START
PLOT PROB, 'lo'=0., 'hi'=1, 'xlog', 'xlo'=0.01, ...
      'xtag'=' -Log PerVan (uM)'
END      '$End of file'

```

```

'FIG 21 B'
PROC NDATA
prepar pconc, prob
set title='BBDR: Effect of Cum.OOH on Mitochondria'
set Nmax=1000.

```

```

DATA
PCONC      PROB      INITIAL
  0.1      1.
10.000    0.9982
20.000    0.9971
30.000    0.9959
40.000    0.9945
50.000    0.9931
60.000    0.9915
70.000    0.9898
80.000    0.9879
90.000    0.9860
100.000   0.9839
110.000   0.9817
120.000   0.9794
130.000   0.9770
140.000   0.9745
150.000   0.9720
160.000   0.9693
170.000   0.9665
180.000   0.9637
190.000   0.9608
200.000   0.9578
210.000   0.9548
220.000   0.9517
230.000   0.9485
240.000   0.9453
250.000   0.9421
260.000   0.9388
270.000   0.9355
280.000   0.9321
290.000   0.9288
300.000   0.9254
310.000   0.9220
320.000   0.9186
330.000   0.9152
340.000   0.9118
350.000   0.9084
360.000   0.9050
370.000   0.9016
380.000   0.8983
390.000   0.8949
400.000   0.8916

```

410.000	0.8882
420.000	0.8850
430.000	0.8817
440.000	0.8785
450.000	0.8753
460.000	0.8721
470.000	0.8690
480.000	0.8659
490.000	0.8629
500.000	0.8599
510.000	0.8569
520.000	0.8540
530.000	0.8511
540.000	0.8483
550.000	0.8455
560.000	0.8428
570.000	0.8401
580.000	0.8375
590.000	0.8349
600.000	0.8324
610.000	0.8299
620.000	0.8275
630.000	0.8251
640.000	0.8228
650.000	0.8206
660.000	0.8183
670.000	0.8162
680.000	0.8141
690.000	0.8120
700.000	0.8100
710.000	0.8080
720.000	0.8061
730.000	0.8043
740.000	0.8024
750.000	0.8007
760.000	0.7990
770.000	0.7973
780.000	0.7957
790.000	0.7941
800.000	0.7925
810.000	0.7911
820.000	0.7896
830.000	0.7882
840.000	0.7868
850.000	0.7855
860.000	0.7842
870.000	0.7830
880.000	0.7818
890.000	0.7806
900.000	0.7795
910.000	0.7784
920.000	0.7773
930.000	0.7763
940.000	0.7753

```

950.000 0.7743
960.000 0.7734
970.000 0.7725
980.000 0.7717
990.000 0.7708
1000.000 0.7700
END      $'END of data'
START
PLOT PROB,'lo'=0.,'hi'=1.,'xlog','xlo'=1.,...
      'xtag'=' -Log Cum.OOH (uM)'
END      $'End of file'

```

```

'FIG 22'
PROC NDATA
prepar pconc,prob
set title='BBDR: Effect of Cum.OOH on Glucose Transporter'
set Nmax=200.
DATA
PCONC      PROB
  0.        1.      INITIAL
 10.000    0.9792
 20.000    0.9487
 30.000    0.9068
 40.000    0.8553
 50.000    0.7963
 60.000    0.7323
 70.000    0.6656
 80.000    0.5984
 90.000    0.5325
100.000    0.4692
110.000    0.4098
120.000    0.3548
130.000    0.3048
140.000    0.2598
150.000    0.2200
160.000    0.1850
170.000    0.1546
180.000    0.1284
190.000    0.1061
200.000    0.0872
END      $'END of data'
START
PLOT PROB,'lo'=0,'hi'=1.,'xtag'=' -Cum.OOH (uM)'
END      $'END of file'

```

```

'FIG 26 B'
PROC NDATA
PREPAR pconc,prob
set title='BBDR: Simulated Effects of TCE on PTyrPase Activity'
set Nmax=50
DATA
PCONC      PROB
  0.500    0.9927
  1.000    0.9883

```

1.500	0.9834
2.000	0.9781
2.500	0.9723
3.000	0.9659
3.500	0.9591
4.000	0.9517
4.500	0.9439
5.000	0.9356
5.500	0.9269
6.000	0.9177
6.500	0.9082
7.000	0.8982
7.500	0.8879
8.000	0.8772
8.500	0.8661
9.000	0.8548
9.500	0.8431
10.000	0.8312
10.500	0.8190
11.000	0.8066
11.500	0.7940
12.000	0.7813
12.500	0.7683
13.000	0.7552
13.500	0.7419
14.000	0.7286
14.500	0.7152
15.000	0.7016
15.500	0.6881
16.000	0.6745
16.500	0.6609
17.000	0.6472
17.500	0.6336
18.000	0.6200
18.500	0.6065
19.000	0.5930
19.500	0.5796
20.000	0.5662
20.500	0.5530
21.000	0.5398
21.500	0.5268
22.000	0.5139
22.500	0.5011
23.000	0.4885
23.500	0.4760
24.000	0.4636
24.500	0.4514
25.000	0.4394
25.500	0.4276
26.000	0.4159
26.500	0.4045
27.000	0.3932
27.500	0.3821
28.000	0.3712

```

28.500  0.3605
29.000  0.3500
29.500  0.3397
30.000  0.3296
30.500  0.3197
31.000  0.3100
31.500  0.3005
32.000  0.2913
32.500  0.2822
33.000  0.2734
33.500  0.2647
34.000  0.2562
34.500  0.2480
35.000  0.2400
35.500  0.2321
36.000  0.2245
36.500  0.2170
37.000  0.2098
37.500  0.2027
38.000  0.1958
38.500  0.1891
39.000  0.1826
39.500  0.1763
40.000  0.1702
40.500  0.1642
41.000  0.1584
41.500  0.1528
42.000  0.1473
42.500  0.1420
43.000  0.1369
43.500  0.1319
44.000  0.1271
44.500  0.1224
45.000  0.1179
45.500  0.1135
46.000  0.1093
46.500  0.1052
47.000  0.1012
47.500  0.0974
48.000  0.0937
48.500  0.0901
49.000  0.0866
49.500  0.0833
50.000  0.0800
END $'End of data'
START
PLOT PROB, 'lo'=0., 'hi'=1., 'xi'=500, 'xtag'='-TCE (umol/g liver)'
END $'End of file'
*****

```